Author: "Clinique Beau Soleil [Montpellier]" / Topic: medicine - Searchworks@Jio Institute Digital Library Search Results

Your search keyword '"Clinique Beau Soleil [Montpellier]"' showing total 56 results

Start Over Author "Clinique Beau Soleil [Montpellier]" Topic medicine

56 results on '"Clinique Beau Soleil [Montpellier]"'

1. Circadian genes polymorphisms, night work and prostate cancer risk: Findings from the EPICAP study

Author: Sylvie Cénée, Anne Boland, Florence Menegaux, Brigitte Trétarre, Pierre Laurent-Puig, Robert Olaso, Xavier Rebillard, Claire Mulot, Hélène Blanché, Pierre-Jean Lamy, Jean-François Deleuze, Thérèse Truong, Geraldine Cancel-Tassin, Olivier Cussenot, Méyomo G. Wendeu-Foyet, Yves Akoli Koudou, Centre de recherche en épidémiologie et santé des populations (CESP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris-Sud - Paris 11 (UP11)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Registre des tumeurs de l'Hérault, CRISAP-LR, COLRIM, EPC du CRLC-Centres privés de radiothérapie de l'Hérault-Laboratoires d'Hématologie CPAM - MSA - Caisse militaire, Clinique Beau Soleil [Montpellier], Centre de Recherche pour les Pathologies Prostatiques [Paris] (CeRePP), Sorbonne Université (SU), Service d'urologie [CHU Tenon], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Tenon [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Sorbonne Université - Département de santé publique, Centre National de Recherche en Génomique Humaine [Évry] (CNRGH), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay, Centre d'Etude du Polymorphisme Humain (CEPH), Institut Universitaire d'Hématologie (IUH), Université Paris Diderot - Paris 7 (UPD7)-Université Paris Diderot - Paris 7 (UPD7)-Fondation Jean Dausset-Université de Paris (UP), Labosud, Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, Agence Nationale de Sécurité Sanitaire de l’Alimentation, de l’Environnement et du Travail, ANSES Ligue Contre le Cancer Fondation ARC pour la Recherche sur le Cancer, ARC Ligue Contre le Cancer Agence Française de Sécurité Sanitaire de l'Environnement et du Travail, AFSSET Institut National Du Cancer, INCa Fondation de France, We would like to thank the clinical research nurses who were in charge of participants’ interview, anthropometric measurements and biological sample collection (Anne‐Laure Astolfi, Coline Bernard, Oriane Boyer, Marie‐Hélène De Campo, Sandrine Margaroli, Louise N'Diaye, Sabine Perrier‐Bonnet). We also would like to thank Christian Prad and Nadine Soller for help with patient medical data collection within the Hérault Cancer Registry (Registre des tumeurs de l'Hérault, Montpellier, France) and Cécile Gaffory and Valérie Ondet for technical assistance (CeRePP). Finally, we are grateful to the EPICAP study Group: Urologists: Drs Didier Ayuso, Bruno Ségui, Vincent Abd El Fattah (Centre Hospitalier Bassin de Thau, Sète, France), Alain Guillaume, Jean‐Paul Constans, Olivier Delbos, Pierre Lanfray, Damien Rizet, Etienne Cuénant (Cabinet Urologie du Polygone, Montpellier, France), Michel Locci (Centre Hospitalier, Béziers, France), Etienne Cuénant (Clinique Ste Thérèse, Sète, France), Nicolas Drianno, Bernard Marc, Paulo Soares (Polyclinique Saint Privat, Béziers, France), Antoine Faix, Samer Abdel Hamid, Bruno Ségui (Service urologie, Clinique Beau Soleil, Montpellier, France), Samer Abdel Hamid (Clinique Saint Louis, Ganges, France), Thibaut Murez, Grégoire Poinas, Laurent Cabaniols, Maxime Robert, Rodolphe Thuret (Centre Hospitalo‐Universitaire, Hôpital Lapeyronie, Montpellier, France). Pathologists: Drs Didier Brel, Lysiane Schweizer, Philippe Nayraud, C. Lecam‐Savin (Inopath‐Biomed 34), Roland Daniel, Jean Baptiste Perdigou, Chantal Compan, Mireille Granier, Agnès Grranier, Ruth Borges‐Reis, Alena Badsi, Jean Louis Bouzigues, Elisabeth Broquerie (Inopath‐Labosud) Joëlle Simony, Frédéric Bibeau, Pierre Baldet, Isabelle Serre, Valérie Costes (Centre Hospitalo‐Universitaire, Hôpital Lapeyronie, Montpellier), Marie Laure Gaume (Sète). Biologists: Drs F. Montels (Service de Biologie Médicale, Institut du Cancer de Montpellier, Montpellier, France) and Labosud laboratories: Drs François et Pascal Dumas (Béziers, France), Martine Buono (Sète, France), Isabelle Bonnefille (Lodeve, France), Georges Ruiz (Lunel, France), Didier Paleirac (Clermont‐l'Hérault, France). The EPICAP‐chrono project was funded by Institut National du Cancer, Fondation ARC and Ligue nationale contre le cancer. The EPICAP study was funded by Ligue nationale contre le cancer, Ligue contre le cancer du Val de Marne, Fondation de France, Agence nationale de sécurité sanitaire de l'alimentation, de l'environnement et du travail (ANSES). The first author has been granted by a Paris‐Sud University doctoral allowance., Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Tenon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), and Université Paris Diderot - Paris 7 (UPD7)-Université Paris Diderot - Paris 7 (UPD7)-Fondation Jean Dausset-Université Paris Cité (UPCité)
Subjects: Adult, Male, Oncology, Cancer Research, medicine.medical_specialty, Genotyping Techniques, Population, interaction, Nerve Tissue Proteins, [SDV.CAN]Life Sciences [q-bio]/Cancer, night work, Polymorphism, Single Nucleotide, 03 medical and health sciences, Prostate cancer, 0302 clinical medicine, Circadian Clocks, Internal medicine, Basic Helix-Loop-Helix Transcription Factors, medicine, Humans, SNP, Genetic Predisposition to Disease, Circadian rhythm, education, Aged, education.field_of_study, NPAS2, business.industry, ARNTL Transcription Factors, Prostatic Neoplasms, Shift Work Schedule, Cancer, Nuclear Receptor Subfamily 1, Group F, Member 1, Odds ratio, Middle Aged, medicine.disease, prostate cancer, 3. Good health, pathway analysis, ARNTL, Logistic Models, Case-Control Studies, 030220 oncology & carcinogenesis, Neoplasm Grading, business, polymorphisms, circadian genes
Abstract: International audience; Over the past two decades, several studies have attempted to understand the hypothesis that disrupting the circadian rhythm may promote the development of cancer. Some have suggested that night work and some circadian genes polymorphisms are associated with cancer, including prostate cancer. Our study aims to test the hypothesis that prostate cancer risk among night workers may be modulated by genetic polymorphisms in the circadian pathway genes based on data from the EPICAP study, a population-based case-control study including 1511 men (732 cases/779 controls) with genotyped data. We estimated odds ratio (ORs) and P values of the association between prostate cancer and circadian gene variants using logistic regression models. We tested the interaction between circadian genes variants and night work indicators that were significantly associated with prostate cancer at pathway, gene and SNP levels. Analyses were also stratified by each of these night work indicators and by cancer aggressiveness. The circadian pathway was significantly associated with aggressive prostate cancer among night workers (P =.004), particularly for men who worked at night for 10 hours, P =.001). At the gene level, we observed among night workers significant associations between aggressive prostate cancer and ARNTL, NPAS2 and RORA. At the SNP-level, no significant association was observed. Our findings provide some clues of a potential modulating effect of circadian genes in the relationship between night work and prostate cancer. Further investigation is warranted to confirm these findings and to better elucidate the biological pathways involved.
Published: 2020

2. Body mass index trajectories and prostate cancer risk: Results from the EPICAP study

Author: Florence Menegaux, Emilie Cordina Duverger, Fanny Artaud, C Lavalette, Brigitte Trétarre, Sylvie Cénée, Pierre-Jean Lamy, Xavier Rebillard, Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, Clinique Beau Soleil [Montpellier], Labosud, Registre des Tumeurs de l'Hérault, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Agence Nationale de Sécurité Sanitaire de l’Alimentation, de l’Environnement et du Travail, ANSES Fondation de France Ligue Contre le Cancer Centre hospitalier universitaire Sainte-Justine, CHUSJ Ligue Contre le Cancer, and The authors thank the clinical research nurses who were in charge of participants' interview, anthropometric measurements and biological sample collection (Anne-Laure Astolfi, Coline Bernard, Oriane Boyer, Marie-H?l?ne De Campo, Sandrine Margaroli, Louise N'Diaye, Sabine Perrier-Bonnet). The authors also thank Christian Prad and Nadine Soller for help with patient medical data collection within the H?rault Cancer Registry (Registre des tumeurs de l'H?rault, Montpellier, France). The authors thank the EPICAP study Group: Urologists: Drs Didier Ayuso, Bruno Segui (Centre Hospitalier Bassin de Thau, S?te, France), Alain Guillaume, Jean-Paul Constans, Olivier Delbos, Pierre Lanfray, Damien Rizet, Etienne Cu?nant?(Cabinet Urologie du Polygone, Montpellier, France), Michel?Locci (Centre Hospitalier, B?ziers, France), Etienne Cu?nant?(Clinique Ste Th?r?se, S?te, France), Nicolas Drianno, Bernard Marc, Paulo Soares (Polyclinique Saint Privat, B?ziers, France), Antoine Faix, Samer Abdel Hamid, Bruno Segui (Service urologie, Clinique Beau Soleil, Montpellier, France), Samer Abdel Hamid (Clinique Saint Louis, Ganges, France), Laurent Cabaniols, Maxime Robert, Rodolphe Thuret (Centre Hospitalo-Universitaire, H?pital Lapeyronie, Montpellier, France). Pathologists: Drs Didier Brel, Lysiane Schweizer, Philippe Nayraud, C. Lecam-Savin (B?ziers), Roland Daniel, Jean Baptiste Perdigou, Chantal Compan, Mireille Granier, Jean Louis Bouzigues, Elisabeth Broquerie, Jo?lle Simony, Fr?d?ric Bibeau, Pierre Baldet, Isabelle Serre (Montpellier), Marie Laure Gaume (S?te). Biologists: Drs Montels (Service de Biologie M?dicale, Institut du Cancer de Montpellier, Montpellier, France), Dumas (B?ziers, France), Buono (S?te, France), Bonnefille (Lodeve, France), Ruiz (Lunel, France), Paleirac (Clermont-l'H?rault, France). Finally, the authors thank Dr Alexis Elbaz, CESP-INSERM Team Exposome, Heredity, Cancer and Health, for his help on BMI trajectories analyses. The EPICAP study was funded by Ligue nationale contre le cancer, Ligue contre le cancer du Val de Marne, Fondation de France, Agence nationale de s?curit? sanitaire de l'alimentation, de l'environnement et du travail (ANSES). The first author, C?line Lavalette, is funded by a 3-year doctoral allowance from the Paris-Saclay University, for her PhD.
Subjects: 0301 basic medicine, Oncology, Male, Risk, Cancer Research, medicine.medical_specialty, obesity, [SDV]Life Sciences [q-bio], body mass index, Overweight, lcsh:RC254-282, 03 medical and health sciences, Prostate cancer, 0302 clinical medicine, Internal medicine, Epidemiology, medicine, Humans, Radiology, Nuclear Medicine and imaging, Original Research, Aged, 2. Zero hunger, Prostate cancer risk, business.industry, Incidence, Age Factors, Prostatic Neoplasms, nutritional and metabolic diseases, weight gain, Non-Smokers, Middle Aged, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, medicine.disease, prostate cancer, Obesity, 3. Good health, 030104 developmental biology, 030220 oncology & carcinogenesis, Case-Control Studies, trajectory, Life course approach, France, medicine.symptom, business, Body mass index, Weight gain, Cancer Prevention
Abstract: Elevated body mass index (BMI) has been inconsistently associated with prostate cancer occurrence but it has been suggested that life course adulthood obesity may be associated with an increased risk of prostate cancer. However, few studies have investigated lifetime BMI and prostate cancer risk. We analyzed life course BMI trajectories on prostate cancer risk based on data from the Epidemiological study of Prostate Cancer (EPICAP). We included in our analyses 781 incident prostate cancer cases and 829 controls frequency matched by age. Participants were asked about their weight every decade from age 20 to two years before reference date. BMI trajectories were determined using group‐based trajectory modeling to identify groups of men with similar patterns of BMI changes. We identified five BMI trajectories groups. Men with a normal BMI at age 20 developing overweight or obesity during adulthood were at increased risk of aggressive prostate cancer compared to men who maintained a normal BMI. Our results suggest that BMI trajectories resulting in overweight or obesity during adulthood are associated with an increased risk of aggressive prostate cancer, particularly in never smokers, emphasizing the importance of maintaining a healthy BMI throughout adulthood., The influence of body weight during lifetime on PCa risk remains largely ununderstood and has been poorly investigated. Our findings suggest that elevated BMI during adulthood resulting in overweight or obesity is associated with an increased risk of aggressive PCa, emphasizing the importance of maintaining a healthy BMI throughout adulthood.
Published: 2020

3. RHESOU (Registre de l’Hérault spécialisé en onco-urologie) : le premier registre français spécialisé en onco-urologie. Un outil méthodologique de recueil de données en onco-urologie. Bilan de faisabilité sur un an d’expérience

Author: R. Guillon, Jean-Pierre Daurès, David Azria, S. Marchal, François Iborra, X. Rebillard, S.G. Trouche-sabatier, I. Serre, O. Lauche, tous les acteurs de l’onco-urologie de l’Hérault, A. Gevorgyan, D. Topart, R. Reis-Borges, G. Poinas, P.-J. Lamy, N. Abdo, Ingrid Millet, Brigitte Trétarre, O. Delbos, CCSD, Accord Elsevier, Registre des Tumeurs de l'Hérault, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Clinique Beau Soleil [Montpellier], Institut de Recherche en Cancérologie de Montpellier (IRCM - U1194 Inserm - UM), CRLCC Val d'Aurelle - Paul Lamarque-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Institut du Cancer de Montpellier (ICM), Urodoc [Montpellier], Polyclinique Saint Privat, Institut médical d'anayse génomique (IMAGENOME), Labosud, Clinique Clémentville [Montpellier], and Inopath Labosud Alco [Montpellier]
Subjects: Registry, MESH: Registries, Epidemiology, Urology, 030232 urology & nephrology, [SDV.MHEP.UN]Life Sciences [q-bio]/Human health and pathology/Urology and Nephrology, 03 medical and health sciences, 0302 clinical medicine, Male genital cancers, Male and female urological cancers, Medicine, Cancers génitaux masculins, MESH: Medical Oncology, MESH: Humans, MESH: Urologic Neoplasms, business.industry, [SDV.MHEP.UN] Life Sciences [q-bio]/Human health and pathology/Urology and Nephrology, MESH: Male, MESH: Urinary Bladder Neoplasms, 3. Good health, Épidémiologie, MESH: France, Cancers urologiques, Registre, MESH: Prostatic Neoplasms, Base de données, Cancers urologiques féminins, Data collection, MESH: Kidney Neoplasms, business, MESH: Female, Humanities
Abstract: Resume Objectifs On observe dans l’Herault une nette augmentation de l’incidence des cancers urologiques. Le registre des tumeurs de l’Herault (RTH) a recueilli 1961 tumeurs urologiques en 2016, soit 21,4 % de l’ensemble des tumeurs de l’Herault pour cette annee-la. La creation d’un registre specialise en onco-urologie nous est apparue necessaire. L’objectif de cet article est de decrire le fonctionnement de RHESOU et de donner quelques exemples de resultats. Materiel et methodes En novembre 2018, RHESOU (Registre de l’herault specialise en onco-urologie) a ete cree sur le meme mode de fonctionnement qu’un registre. Il permet de completer les donnees du RTH sur beaucoup d’autres parametres oncologiques. Pour chaque type de cancer urologique et genital masculin et urologique feminin, une fiche de recueil a ete realisee pour recueillir le maximum de donnees presentes dans le dossier des cas signales. Cette etude a evalue les donnees concernant les patients domicilies dans l’Herault pour l’annee 2017. Resultats Nous avons denombre pour l’annee 2017, 970 cancers de la prostate, 581 tumeurs de vessie, 212 cancers du rein, 51 tumeurs de la voie excretrice superieure, 28 cancers du testicule et 9 cancers du penis. Le recueil de ces donnees permet de creer des requetes et de fournir des analyses pertinentes et detaillees sur les cancers urologiques et genitaux masculins. Nous rapportons les donnees analysees sur le rein, la vessie et la prostate. Conclusions RHESOU est un outil accessible pour permettre une vue d’ensemble sur les cancers en urologie dans l’Herault et leur prise en charge. Avec l’apparition de nouveaux traitements, il saura s’adapter en permettant une evolution des fiches. Niveau de preuve 3.
Published: 2020

4. Matching Graft Quality to Recipient’s Disease Severity Based on the Survival Benefit in Liver Transplantation

Author: Jean-Pierre Daurès, Cyrille Feray, Audrey Winter, Daniel Azoulay, Corinne Antoine, Paul Landais, Aide à la Décision pour une Médecine Personnalisé - Laboratoire de Biostatistique, Epidémiologie et Recherche Clinique - EA 2415 (AIDMP), Université Montpellier 1 (UM1)-Université de Montpellier (UM), Clinique Beau Soleil [Montpellier], University of California [Los Angeles] (UCLA), University of California, Physiopathologie et traitement des maladies du foie, Université Paris-Sud - Paris 11 (UP11)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM), Agence de la biomédecine [Saint-Denis la Plaine], This work was funded by a grant of the French Ministry of Health and Social Affairs. The present study is part of the 'OPTIMATCH' program funded by the French Ministry of Health within the framework of the national Clinical Research Hospital Program., Bodescot, Myriam, and University of California (UC)
Subjects: Adult, Male, Quality Control, medicine.medical_specialty, Epidemiology, medicine.medical_treatment, Population, lcsh:Medicine, 030230 surgery, Liver transplantation, Gastroenterology, Article, 03 medical and health sciences, Liver disease, 0302 clinical medicine, Disease severity, Internal medicine, medicine, Humans, Prospective Studies, education, lcsh:Science, education.field_of_study, Multidisciplinary, Proportional hazards model, business.industry, Liver Diseases, Statistics, Hazard ratio, lcsh:R, Patient Acuity, [SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, medicine.disease, Survival Analysis, [SDV.MHEP.HEG] Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, Liver Transplantation, 3. Good health, Transplantation, body regions, Survival benefit, Liver cirrhosis, Female, 030211 gastroenterology & hepatology, lcsh:Q, business, Liver cancer
Abstract: Persistent shortage and heterogeneous quality of liver grafts encourages the optimization of donor-recipient matching in liver transplantation (LT). We explored whether or not there was a survival benefit (SB) of LT according to the quality of grafts assessed by the Donor Quality Index (DQI) and recipients’ disease severity, using the Model for End-Stage Liver Disease (MELD) in 8387 French patients wait-listed between 2009 and 2014. SB associated with LT was estimated using the sequential stratification method in different categories of MELD and DQI. For each transplantation, a stratum was created that matched one transplanted patient with all eligible control candidates. Strata were thereafter combined, and a stratified Cox model, adjusted for covariates, was fitted in order to estimate hazard ratios that qualified the SB according to each MELD and DQI sub-group. A significant SB was observed for all MELD and DQI sub-groups, with the exception of high MELD patients transplanted with “high-risk” grafts. More specifically, in decompensated-cirrhosis patients, “high-risk” grafts did not appear to be detrimental in medium MELD patients. Interestingly, in hepatocellular-carcinoma (HCC) patients, a significant SB was found for all MELD-DQI combinations. For MELD exceptions no SB was found. In terms of SB, “low-risk” grafts appeared appropriate for most severe patients (MELD > 30). Conversely, low/medium MELD and HCC patients presented an SB while allocated “high-risk” grafts. Thus, SB based matching rules for LT candidates might improve the survival of the LT population as a whole.
Published: 2020

5. Fine‐Mapping of SNCA in Rapid Eye Movement Sleep Behavior Disorder and Overt Synucleinopathies

Author: Edward A. Fon, Armaghan Alam, Richard Y.J. Wu, Cornelis Blauwendraat, Jennifer A. Ruskey, Luigi Ferini-Strambi, Paul Cannon, Mathias Toft, Mariarosaria Valente, Alex Desautels, Andrew B. Singleton, Valérie Cochen De Cock, Yves Dauvilliers, Elena Antelmi, C. Trenkwalder, Kari Anne Bjørnarå, Abril Beatriz, Christelle Charley Monaca, Jacques Montplaisir, Nicolas Dupré, Mineke Viaene, Peter Young, Birgit Högl, Giuseppe Plazzi, Monica Puligheddu, W. H. Oertel, Marco Toffoli, Bradley F. Boeve, Owen A. Ross, Friederike Sixel-Döring, Lasse Pihlstrøm, Michele T.M. Hu, Isabelle Arnulf, Sandra B. Laurent, Karl Heilbron, Michela Figorilli, Anna Heidbreder, Lynne Krohn, Guy A. Rouleau, Karel Sonka, Ziv Gan-Or, Mike A. Nalls, Jean-François Gagnon, David Kemlink, Evi Holzknecht, Femke Dijkstra, Ambra Stefani, Gian Luigi Gigli, Brit Mollenhauer, Ronald B. Postuma, Krohn L., Wu R.Y.J., Heilbron K., Ruskey J.A., Laurent S.B., Blauwendraat C., Alam A., Arnulf I., Hu M.T.M., Dauvilliers Y., Hogl B., Toft M., Bjornara K.A., Stefani A., Holzknecht E., Monaca C.C., Abril B., Plazzi G., Antelmi E., Ferini-Strambi L., Young P., Heidbreder A., Cochen De Cock V., Mollenhauer B., Sixel-Doring F., Trenkwalder C., Sonka K., Kemlink D., Figorilli M., Puligheddu M., Dijkstra F., Viaene M., Oertel W., Toffoli M., Gigli G.L., Valente M., Gagnon J.-F., Nalls M.A., Singleton A.B., Desautels A., Montplaisir J.Y., Cannon P., Ross O.A., Boeve B.F., Dupre N., Fon E.A., Postuma R.B., Pihlstrom L., Rouleau G.A., Gan-Or Z., Krohn, L., R. Y. J., Wu, Heilbron, K., Ruskey, J. A., Laurent, S. B., Blauwendraat, C., Alam, A., Arnulf, I., M. T. M., Hu, Dauvilliers, Y., Hogl, B., Toft, M., Bjornara, K. A., Stefani, A., Holzknecht, E., Monaca, C. C., Abril, B., Plazzi, G., Antelmi, E., Ferini-Strambi, L., Young, P., Heidbreder, A., Cochen De Cock, V., Mollenhauer, B., Sixel-Doring, F., Trenkwalder, C., Sonka, K., Kemlink, D., Figorilli, M., Puligheddu, M., Dijkstra, F., Viaene, M., Oertel, W., Toffoli, M., Gigli, G. L., Valente, M., Gagnon, J. -F., Nalls, M. A., Singleton, A. B., Desautels, A., Montplaisir, J. Y., Cannon, P., Ross, O. A., Boeve, B. F., Dupre, N., Fon, E. A., Postuma, R. B., Pihlstrom, L., Rouleau, G. A., Gan-Or, Z., McGill University Health Center [Montreal] (MUHC), Montreal Neurological Institute and Hospital, McGill University = Université McGill [Montréal, Canada], Imperial College London, 23andMe Inc., National Institute on Aging [Bethesda, USA] (NIA), National Institutes of Health [Bethesda] (NIH), Centre d'investigation clinique Neurosciences [CHU Pitié Salpêtrière] (CIC Neurosciences), CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), University of Oxford [Oxford], Nuffield Department of Clinical Neurosciences [Oxford], Département de neurologie [Montpellier], Hôpital Gui de Chauliac [Montpellier]-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Université Montpellier 1 (UM1)-Université de Montpellier (UM), Innsbruck Medical University [Austria] (IMU), Oslo University Hospital [Oslo], Service de neurophysiologie clinique (CHRU Lille), Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Hôpital Universitaire Carémeau [Nîmes] (CHU Nîmes), Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), Alma Mater Studiorum University of Bologna (UNIBO), University of Bologna, Department of Biomedical and Neuromotor Sciences [Bologna, Italy], Universita Vita Salute San Raffaele = Vita-Salute San Raffaele University [Milan, Italie] (UniSR), University of Münster, Clinique Beau Soleil [Montpellier], EuroMov - Digital Health in Motion (Euromov DHM), IMT - MINES ALES (IMT - MINES ALES), Institut Mines-Télécom [Paris] (IMT)-Institut Mines-Télécom [Paris] (IMT)-Université de Montpellier (UM), Paracelsus-Elena-Klinik, Kassel, Germany., University Medical Center Göttingen (UMG), First Faculty of Medicine Charles University [Prague], Universita degli Studi di Cagliari [Cagliari], Algemeen Ziekenhuis Sint-Dimpna, Philipps University of Marburg, Università degli Studi di Udine - University of Udine [Italie], University College of London [London] (UCL), Department of Mathematics and Computer Science [Udine], Hôpital du Sacré-Coeur de Montréal, Université du Québec à Montréal = University of Québec in Montréal (UQAM), Data Tecnica International, Centre d'études avancées en Médecine du Sommeil (CEAMS), Université de Montréal (UdeM)-Hôpital du Sacré-Coeur de Montréal, Mayo Clinic [Jacksonville], Mayo Clinic [Rochester], Laval University Medical center, and Université Laval [Québec] (ULaval)
Subjects: Male, 0301 basic medicine, Oncology, Linkage disequilibrium, Synucleinopathies, REM sleep behavior disorder, MESH: Logistic Models, REM Sleep Behavior Disorder, 0302 clinical medicine, synucleinopathy, SNCA, Odds Ratio, RBD-specific risk variants, MESH: Aged, MESH: Middle Aged, Rapid eye movement sleep behavior disorder (RBD), MESH: Polymorphism, Single Nucleotide, MESH: Genetic Predisposition to Disease, Parkinson Disease, Middle Aged, MESH: Case-Control Studies, 3. Good health, Neurology, MESH: Synucleinopathies, alpha-Synuclein, Female, Adult, Lewy Body Disease, medicine.medical_specialty, Prodromal Symptoms, Single-nucleotide polymorphism, Locus (genetics), Polymorphism, Single Nucleotide, Article, 03 medical and health sciences, Internal medicine, MESH: alpha-Synuclein, medicine, Humans, Genetic Predisposition to Disease, MESH: Prodromal Symptoms, Allele frequency, MESH: Lewy Body Disease, Aged, MESH: Humans, business.industry, Dementia with Lewy bodies, [SCCO.NEUR]Cognitive science/Neuroscience, MESH: Adult, Odds ratio, medicine.disease, MESH: Odds Ratio, MESH: Male, synucleinopathies, Logistic Models, 030104 developmental biology, MESH: REM Sleep Behavior Disorder, [SDV.GEN.GH]Life Sciences [q-bio]/Genetics/Human genetics, Case-Control Studies, Synuclein, Neurology (clinical), business, MESH: Female, MESH: Parkinson Disease, 030217 neurology & neurosurgery
Abstract: Objective: Rapid eye movement sleep behavior disorder (RBD) is a prodromal synucleinopathy, as >80% will eventually convert to overt synucleinopathy. We performed an in-depth analysis of the SNCA locus to identify RBD-specific risk variants. Methods: Full sequencing and genotyping of SNCA was performed in isolated/idiopathic RBD (iRBD, n = 1,076), Parkinson disease (PD, n = 1,013), dementia with Lewy bodies (DLB, n = 415), and control subjects (n = 6,155). The iRBD cases were diagnosed with RBD prior to neurodegeneration, although some have since converted. A replication cohort from 23andMe of PD patients with probable RBD (pRBD) was also analyzed (n = 1,782 cases; n = 131,250 controls). Adjusted logistic regression models and meta-analyses were performed. Effects on conversion rate were analyzed in 432 RBD patients with available data using Kaplan–Meier survival analysis. Results: A 5′-region SNCA variant (rs10005233) was associated with iRBD (odds ratio [OR] = 1.43, p = 1.1E-08), which was replicated in pRBD. This variant is in linkage disequilibrium (LD) with other 5′ risk variants across the different synucleinopathies. An independent iRBD-specific suggestive association (rs11732740) was detected at the 3′ of SNCA (OR = 1.32, p = 4.7E-04, not statistically significant after Bonferroni correction). Homozygous carriers of both iRBD-specific SNPs were at highly increased risk for iRBD (OR = 5.74, p = 2E-06). The known top PD-associated variant (3′ variant rs356182) had an opposite direction of effect in iRBD compared to PD. Interpretation: There is a distinct pattern of association at the SNCA locus in RBD as compared to PD, with an opposite direction of effect at the 3′ of SNCA. Several 5′ SNCA variants are associated with iRBD and with pRBD in overt synucleinopathies. ANN NEUROL 2020;87:584–598.
Published: 2020

6. Mandibular advancement device in Parkinson's disease: a pilot study on efficacy and usability

Author: Manon Castel, Hervé Leon, Valérie Cochen De Cock, Isabelle Dupuy-Bonafé, Faculté d'odontologie [Montpellier], Université de Montpellier (UM), Clinique Beau Soleil [Montpellier], EuroMov - Digital Health in Motion (Euromov DHM), IMT - MINES ALES (IMT - MINES ALES), Institut Mines-Télécom [Paris] (IMT)-Institut Mines-Télécom [Paris] (IMT)-Université de Montpellier (UM), Hôpital Universitaire Carémeau [Nîmes] (CHU Nîmes), and Centre Hospitalier Universitaire de Nîmes (CHU Nîmes)
Subjects: Male, MESH: Continuous Positive Airway Pressure, Parkinson's disease, medicine.medical_treatment, MESH: Sleep Apnea, Obstructive, Pilot Projects, Disease, 0302 clinical medicine, Surveys and Questionnaires, Mandibular advancement device, Continuous positive airway pressure, MESH: Treatment Outcome, 2. Zero hunger, Sleep Apnea, Obstructive, education.field_of_study, MESH: Middle Aged, Continuous Positive Airway Pressure, Parkinson Disease, General Medicine, Middle Aged, 3. Good health, Obstructive sleep apnea syndrome, Treatment Outcome, MESH: Mandibular Advancement, [SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC], Female, Mandibular Advancement, medicine.medical_specialty, animal structures, Population, Disabled Population, 03 medical and health sciences, Internal medicine, medicine, Humans, MESH: Surveys and Questionnaires, education, MESH: Humans, business.industry, Usability, MESH: Pilot Projects, medicine.disease, MESH: Male, nervous system diseases, respiratory tract diseases, Obstructive sleep apnea, 030228 respiratory system, business, MESH: Female, Body mass index, MESH: Parkinson Disease, 030217 neurology & neurosurgery
Abstract: International audience; Continuous positive airway pressure (CPAP) is efficacious in the treatment of obstructive sleep apnea syndrome (OSAS) in patients with Parkinson's disease (PD). However, this treatment is often not well tolerated in this disabled population. We explored, in a pilot study, the efficacy, observance, and usability of mandibular advancement device (MAD) for the treatment of OSAS in this peculiar population. Patients/methods: Twenty patients with PD and moderate or severe OSAS were included in the study. Ten patients had refused or not tolerated the validated treatment with CPAP so that they were treated with MAD. The patients treated with MAD were matched for sex, age and body mass index (BMI) to 10 patients with PD treated with CPAP. We explored the efficacy of MAD on sleep disorders complaints (PDSS-2) and on sleep recordings. We compared adherence, tolerance and usability with MAD and with CPAP.Results: MAD improved sleep complaints increasing PDSS-2 scores (85 [55-106] vs 106 [88-126], p < 0.005), and sleep respiratory measures reducing apnea/hypopnea index (AHI) (50.8 [30.0-76.4] vs 9.4 [5.0-45.2]
Published: 2020

7. Endoscopic Nipple-Sparing Mastectomy with Immediate Prepectoral Implant-Based Reconstruction: A Case Report

Author: Christophe Bonnel, Guillaume Captier, Martha Duraes, Gauthier Rathat, Christian Herlin, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Hôpital Lapeyronie [Montpellier] (CHU), Laboratoire d'Anatomie [CHU Montpellier], and Clinique Beau Soleil [Montpellier]
Subjects: medicine.medical_specialty, Breast Implants, Mammaplasty, Mastectomy, Subcutaneous, medicine.medical_treatment, Axillary lines, [SDV.CAN]Life Sciences [q-bio]/Cancer, Breast Neoplasms, Adenocarcinoma, 030204 cardiovascular system & hematology, 03 medical and health sciences, 0302 clinical medicine, Patient satisfaction, medicine, Humans, Breast Implantation, business.industry, Pectoralis major muscle, Endoscopy, Prophylactic Mastectomy, Articles, General Medicine, Implant-based reconstruction (IBR), Middle Aged, Endoscopic surgery, nipple-sparing mastectomy (NSM), 3. Good health, Surgery, Nipples, 030220 oncology & carcinogenesis, Female, Implant, business, Breast reconstruction, Organ Sparing Treatments, Mastectomy
Abstract: Patient: Female, 45-year-old Final Diagnosis: Prophylactic mastectomy Symptoms: — Medication: — Clinical Procedure: — Specialty: Obstetrics and Gynecology Objective: Unusual setting of medical care Background: Technical innovations allow endoscopic nipple-sparing mastectomy (NSM), which is well tolerated and associated with greater patient satisfaction. Endoscopic technique did not have wide diffusion; many centers have abandoned this technique because of technical challenges. Implant-based reconstruction (IBR) remains the most common form of breast reconstruction. Current techniques involve partial or total coverage of the implant with pectoralis major muscle to prevent exposure or infection. Muscle dissection has functional and cosmetic consequences. Case Report: We present a case of 45-year-old patient presenting with personal history of right breast cancer. The patient requested left prophylactic mastectomy. We used a 4 cm-long single hidden scar on axillary line. Endoscopic nipple-sparing mastectomy was done using a single port with 3 sleeves. Immediate breast reconstruction was performed by inserting a silicon implant in prepectoral plane without Acellular Dermal Matrix (ADM). At 6 months postoperatively, no complication had been reported. The patient was satisfied with the result and no further correction was necessary. Conclusions: Endoscopic surgery is a valuable option for nipple-sparing mastectomy. This method is a less expensive alternative technique to robotic approach. It could enable safe prepectoral IBR without placement of ADM and with lower risk of complications.
Published: 2019

8. Serious complications and recurrences after pelvic organ prolapse surgery for 2309 women in the VIGI‐MESH registry

Author: X Fritel, R Tayrac, J Keizer, S Campagne‐Loiseau, M Cosson, P Ferry, X Deffieux, J‐P Lucot, L Wagner, P Debodinance, C Saussine, A‐C Pizzoferrato, C Carlier‐Guérin, T Thubert, L Panel, P‐O Bosset, E Nkounkou, R Ramanah, T Boisramé, T Charles, C Raiffort, A Charvériat, S Ragot, A Fauconnier, Adnan Aboukassem, Chérif Akladios, Emmanuelle Arsène, Jean‐Sébastien Aucouturier, Georges Bader, Emmanuel Bailly, Jean‐Jacques Baldauf, Stéphanie Bartolo, Marie‐Line Barussaud, Fanny Béchard, Simon Bernardeau, Clément Biscans, Deepak Boodhun, Revaz Botchorishvili, Michel Boukaram, Aude Brams, Laurent Bressler, Clément Bruhat, Michel Canis, Victor Cavillon, Olivier Celhay, Armand Chevrot, Pierre Collinet, Arnaud Cornille, Pierre Costa, Christophe Courtieu, Laurent Courtois, Sandra Curinier, Eric Darnis, Pierre‐Olivier Delpech, Véronique Delporte, Anne Dubois, Emilie Faller, Brigitte Fatton, Cécile Féyeux, Victor Gabriele, Pierre Gadonneix, Olivier Garbin, Florent Genty, Géraldine Giraudet, Pascale Gres, Pauline Gueudry, Jean‐François Haab, Audrey Hedde, Aline Host, Michel Hummel, Estelle Jean dit Gautier, Aminata Kane, Sophie Gouic, Isabelle Teuff, Gil Lebreton, Lise Lecointre, Grégoire Léon, Yolande Maisonnette, Lucile Martin, Aurore Marx, Pascal Mouracade, Corinne Palamara, Petit Nicolas, Caroline Pettenati, Laurence Peyrat, Pierre Pillot, Jean‐Luc Pouly, Clothilde Poupon, Michel Prudhomme, Benoît Rabishong, Hélène Ricard, Jérémie Ripoche, Géraldine Rivaux, Jennifer Salerno, Delphine Salet‐Lizée, Richard Sarfati, Maxence Sarradin, Elodie Schuller, An Segaert, François Stoll, Yannick Thirouard, Caroline Trichot, Mélusine Turck, David Vandendriessche, Edouard Vaucel, Sarah Vieillefosse, Anne Villot, Denis Vinatier, Etienne Vincens, Marie Vinchant, Béatrice Vinson‐Bonnet, Soraya Wapler, Sophie Warembourg, CIC - Poitiers, Université de Poitiers-Centre hospitalier universitaire de Poitiers (CHU Poitiers)-Direction Générale de l'Organisation des Soins (DGOS)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre hospitalier universitaire de Poitiers (CHU Poitiers), Hôpital Universitaire Carémeau [Nîmes] (CHU Nîmes), Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), CHU Estaing [Clermont-Ferrand], CHU Clermont-Ferrand, CHU Lille, Hôpital Saint-Louis de La Rochelle (CH La Rochelle), AP-HP - Hôpital Antoine Béclère [Clamart], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Hôpital Saint Vincent de Paul de Lille, Groupement des Hôpitaux de l'Institut Catholique de Lille (GHICL), Université catholique de Lille (UCL)-Université catholique de Lille (UCL), CH Dunkerque, CHU Strasbourg, CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN), CH de Châtellerault, Centre hospitalier universitaire de Nantes (CHU Nantes), Clinique Beau Soleil [Montpellier], Hôpital Foch [Suresnes], Centre Hospitalier de Béthune (CH Béthune), GHT de l'Artois, Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Groupe Hospitalier Diaconesses Croix Saint-Simon, Centre hospitalier intercommunal de Poissy/Saint-Germain-en-Laye - CHIPS [Poissy], Fritel, Xavier, Groupe Hospitalier de l'Institut Catholique de Lille (GHICL), and centre hospitalier intercommunal de Poissy/Saint-Germain-en-Laye - CHIPS [Poissy]
Subjects: Reoperation, medicine.medical_specialty, Multivariate analysis, [SDV]Life Sciences [q-bio], Population, registry, [SDV.MHEP.GEO]Life Sciences [q-bio]/Human health and pathology/Gynecology and obstetrics, Risk profile, 03 medical and health sciences, Gynecologic Surgical Procedures, Postoperative Complications, 0302 clinical medicine, surgical complication, Recurrence, Risk Factors, Humans, Medicine, Prospective Studies, Registries, 030212 general & internal medicine, education, Prospective cohort study, Aged, Pelvic organ, education.field_of_study, 030219 obstetrics & reproductive medicine, business.industry, Prolapse surgery, Incidence (epidemiology), Hazard ratio, Obstetrics and Gynecology, Middle Aged, Surgical Mesh, Vaginal repair, pelvic organ prolapse, Confidence interval, 3. Good health, Surgery, [SDV] Life Sciences [q-bio], [SDV.MHEP.GEO] Life Sciences [q-bio]/Human health and pathology/Gynecology and obstetrics, mesh, Vagina, Female, Laparoscopy, Longitudinal study, business
Abstract: Objective To assess the incidence of serious complications and reoperations for recurrence after surgery for pelvic organ prolapse (POP) and compare the three most common types of repair. Design Prospective cohort study using a registry. Setting Nineteen French surgical centres. Population A total of 2309 women participated between 2017 and 2019. Methods A multivariate analysis including an inverse probability of treatment weighting approach was used to obtain three comparable groups. Main outcome measures Serious complications and subsequent reoperations for POP recurrence. Results The median follow-up time was 17.6 months. Surgeries were native tissue vaginal repairs (n = 504), transvaginal mesh placements (n = 692) and laparoscopic sacropexies with mesh (n = 1113). Serious complications occurred among 52 women (2.3%), and reoperation for POP recurrence was required for 32 women (1.4%). At 1 year the cumulative weighted incidence of serious complications was 1.8% for native tissue vaginal repair, 3.9% for transvaginal mesh and 2.2% for sacropexy, and the rates for reoperation for recurrence of POP were 1.5, 0.7 and 1.1%, respectively. Compared with native tissue vaginal repair, the risk of serious complications was higher in the transvaginal mesh group (weighted hazard ratio, wHR 3.84, 95% CI 2.43-6.08) and the sacropexy group (wHR 2.48, 95% CI 1.45-4.23), whereas the risk of reoperation for prolapse recurrence was lower in both the transvaginal mesh (wHR 0.22, 95% CI 0.13-0.39) and sacropexy (wHR 0.29, 95% CI 0.18-0.47) groups. Conclusions Our results suggest that native tissue vaginal repairs have the lowest risk of serious complications but the highest risk of reoperation for recurrence. These results are useful for informing women and for shared decision making. Tweetable abstract Laparoscopic sacropexy had fewer serious complications than transvaginal mesh and fewer reoperations for recurrence than vaginal repair.
Published: 2021

9. Baseline Characteristics of a National French E-Cohort of Hidradenitis Suppurativa in ComPaRe and Comparison with Other Large Hidradenitis Suppurativa Cohorts

Author: Marie-France Bru, Laetitia Penso, Hervé Bachelez, Eric Jacquet, Viet-Thi Tran, Pierre Perrot, Marie-Aleth Richard, C. Hotz, Axel Patrice Villani, Emilie Sbidian, M. Viguier, Pierre Wolkenstein, Morgane Condamina, Philippe Ravaud, Aude Nassif, Marie Beylot-Barry, Philippe Guillem, Centre Hospitalier Universitaire de Reims (CHU Reims), Epidemiology in Dermatology and Evaluation in Therapeutics (EpiDermE), Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Agence nationale de sécurité du médicament et des produits de santé [Saint-Denis] (ANSM), Centre de Recherche Épidémiologie et Statistique Sorbonne Paris Cité (CRESS (U1153 / UMR_A_1125 / UMR_S_1153)), Conservatoire National des Arts et Métiers [CNAM] (CNAM), HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Hôtel-Dieu, CHU Henri Mondor, Hôpital Edouard Herriot [CHU - HCL], Hospices Civils de Lyon (HCL), Sarcomes osseux et remodelage des tissus calcifiés - Phy-Os [Nantes - INSERM U1238] (Phy-Os), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Bretagne Loire (UBL)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN), Institut de Chimie des Substances Naturelles (ICSN), Institut de Chimie du CNRS (INC)-Université Paris-Saclay-Centre National de la Recherche Scientifique (CNRS), Centre Médical de l'Institut Pasteur (CMIP), Institut Pasteur [Paris], Imagine - Institut des maladies génétiques (IHU) (Imagine - U1163), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), Hopital Saint-Louis [AP-HP] (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Hôpital Henri Mondor, Université Paris-Est Créteil Val-de-Marne - Faculté de médecine (UPEC Médecine), Service de dermatologie [Bordeaux], Université Bordeaux Segalen - Bordeaux 2-CHU Bordeaux [Bordeaux]-Hôpital Haut-Lévêque [CHU Bordeaux], CHU Bordeaux [Bordeaux], Hôpital de la Timone [CHU - APHM] (TIMONE), Hôpital Hôtel-Dieu [Paris], French Cochrane Centre, Service de dermatologie [Mondor], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), HESAM Université (HESAM)-HESAM Université (HESAM)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPC)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Service de dermatologie [HCL Lyon], Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPC), Cochrane France [Paris], Service de dermatologie (CHU de Reims), Clinique du Val d'Ouest, Hôtel-Dieu de Nantes, Clinique Beau Soleil [Montpellier], Institut Pasteur [Paris] (IP), Bordeaux Research In Translational Oncology [Bordeaux] (BaRITOn), Université de Bordeaux (UB)-CHU Bordeaux [Bordeaux]-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre d'études et de recherche sur les services de santé et la qualité de vie (CEReSS), Aix Marseille Université (AMU), Centre d'Investigation Clinique Henri Mondor (CIC Henri Mondor), and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)
Subjects: Adult, Male, medicine.medical_specialty, Sociodemographic Factors, Dermatology, Disease, Overweight, Severity of Illness Index, Cohort Studies, Young Adult, Quality of life, Internal medicine, Epidemiology, Humans, Medicine, Sex organ, Hidradenitis suppurativa, Family history, business.industry, medicine.disease, Hidradenitis Suppurativa, Cohort, Quality of Life, Female, France, medicine.symptom, business, [SDV.MHEP.DERM]Life Sciences [q-bio]/Human health and pathology/Dermatology
Abstract: Background: Hidradenitis suppurativa (HS) is a chronic inflammatory skin condition substantially impacting patients’ quality of life; the pathogenesis remains unclear, and treatment is complex and not yet standardized. Observational data are increasingly being used to evaluate therapeutics in “real-life” interventions, and the development of e-cohorts is offering new tools for epidemiological studies at the population level. Objective: The aim of this study was to describe the clinical characteristics and treatment history of HS participants in the Community of Patients for Research (ComPaRe) cohort and to compare these to other cohorts. Methods: We performed a cross-sectional study of the baseline data of HS participants in ComPaRe, an e-cohort of patients with chronic diseases. Data were collected using patient-reported questionnaires about clinical-demographic aspects, quality of life, and treatment history. Results: A total of 396 participants (339 females, 57 males) were included (mean age 38 years); 83 (21%) had a family history of HS, 227 (57.3%) were current smokers, and 241 (60.9%) were overweight or obese. Most of the participants declared a Hurley stage II (n = 263, 66.4%) or III (n = 76, 20.3%). The breast was more frequently affected in women than men (37.5 vs. 5.3%, p < 0.0001), whereas the dorsal region was more frequently affected in men (39.5 vs. 10.9%, p < 0.0001). Increased disease stage was associated with obesity (25.9 vs. 33.8 vs. 51.3%, p = 0.02) and some HS localizations (genital [p < 0.005], pubis [p < 0.007], gluteal fold [p = 0.02], and groin [p < 0.0001]). The most frequently prescribed treatments were oral antibiotics (n = 362, 91.4%), especially amoxicillin-clavulanic acid and cyclins. Less than 10% of participants received biologics. Most of these results were consistent with previously published cohorts. Conclusion: Recruitment of participants by such a web platform can be a faster way to get relevant scientific data for a wide variety of patients that could be used for epidemiological studies and to evaluate therapeutics in “real-life” interventions.
Published: 2021

10. Recommandations pour l'évaluation et la prise en charge de la maladie de Lapeyronie : rapport du comité d'andrologie et de médecine sexuelle de l'AFU

Author: D. Carnicelli, C. Methorst, Jean-Etienne Terrier, V. Hupertan, R. Yiou, L. Ferretti, N. Morel Journel, L. Savareux, E. Huyghe, F.X. Madec, J.-P. Graziana, A. Faix, François Marcelli, W. Akakpo, S. Beley, K. Ben-Naoum, Hôpital d'Instruction des Armées Robert Picqué, Service de Santé des Armées, Hôpital Foch [Suresnes], CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Service d'urologie, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Anthropologie bio-culturelle, Droit, Ethique et Santé (ADES), Aix Marseille Université (AMU)-EFS ALPES MEDITERRANEE-Centre National de la Recherche Scientifique (CNRS), Clinique Turin, Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), Clinique Beau Soleil [Montpellier], Gestionnaire, HAL Sorbonne Université 5, Service d'Urologie [CHU Pitié-Salpêtrière], and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)
Subjects: Implant pénien, medicine.medical_specialty, Greffe, French, Urology, Peyronie's disease, 030232 urology & nephrology, Penile prosthesis, Guideline, [SDV.MHEP.UN]Life Sciences [q-bio]/Human health and pathology/Urology and Nephrology, Graft, 03 medical and health sciences, 0302 clinical medicine, Medical, Plication, Medicine, Médical, Evaluation, Traitement, Chirurgie, Gynecology, Recommandation, business.industry, [SDV.MHEP.UN] Life Sciences [q-bio]/Human health and pathology/Urology and Nephrology, language.human_language, Français, Treatment, Maladie de Lapeyronie, Évaluation, Plicature, language, Surgery, business
Abstract: IntroductionPeyronie's disease is a common cause for consultation in urology. Many controversies surround its treatment. No French Guidelines have been published so far. The Committee of Andrology and Sexual Medicine of the French Association of Urology therefore offers a series of evidence-based recommendations.Materials and methodsThese recommendations are made according to the ADAPTE method, based on European (EAU, ESSM), American (AUA, ISSM) and Canadian (CAU) recommendations, integrating French specificities due to the availability of treatments, and an update of the recent bibliography.ResultsThe assessment of the disease is clinical. Patients with functional impairment or significant psychological repercussions may be offered treatment. The benefits and drawbacks of each treatment should be explained to the patient. Regarding non-surgical treatments, no available treatment has market authorization in France. Vitamin E is not recommended. Analgesic (oral or low-intensity shock waves) or proerectile treatments may be offered as needed, as well as traction therapy. Due to the unavailability of collagenase injections, verapamil injections may be offered. Surgical treatments are to be considered in the stabilized phase of the disease, and consist of performing a plication, an incision-graft or the placement of a penile implant according to the patient's wishes, the curvature and the penis size, as well as erectile function. Combination treatments can be offered.ConclusionThe management of Peyronie's disease is complex, and the levels of evidence for treatments are generally low. The success of treatment will depend on the quality of the initial assessment, the patient's information and understanding of the expected effects, and the practitioner's experience., IntroductionLa maladie de Lapeyronie est un motif fréquent de consultation en urologie, dont le traitement reste sujet à de nombreuses controverses. Elle n’a fait l’objet d’aucune recommandation française jusqu’à présent. Le Comité d’Andrologie et de Médecine Sexuelle de l’Association Française d’Urologie propose donc une série de recommandations basées sur les preuves.Matériels et méthodesCes recommandations sont réalisées selon la méthode ADAPTE, en se basant sur les recommandations européennes (EAU, ESSM), américaines (AUA, ISSM) et canadiennes (CAU), en intégrant les spécificités françaises en raison de la disponibilité des traitements, et une mise à jour de la bibliographie récente.RésultatsL’évaluation de la maladie est clinique. Les patients présentant une gêne fonctionnelle ou un retentissement psychologique important peuvent se voir proposer un traitement. Les bénéfices et inconvénients de chaque traitement devront être explicités au patient. Concernant les traitements non chirurgicaux, aucun traitement disponible n’a l’autorisation de mise sur le marché en France. La vitamine E n’est pas recommandée. Des traitements à visée antalgiques (oraux ou ondes de choc de faible intensité) ou pro-érectiles peuvent être proposée selon le besoin, ainsi qu’une thérapie par traction. En raison de l’indisponibilité des injections de collagénase, les injections de vérapamil peuvent être proposées. Les traitements chirurgicaux sont à considérer en phase stabilisée de la maladie, et consistent en la réalisation d’une plicature, d’une incision-greffe ou de la pose d’un implant pénien en fonction du souhait du patient, de la courbure et de la taille de verge, ainsi que de la fonction érectile. Des traitements combinés peuvent être proposés.ConclusionLa prise en charge de la maladie de Lapeyronie est complexe, et les niveaux de preuve des traitements sont faibles dans l’ensemble. Le succès du traitement dépendra de la qualité de l’évaluation initiale, de l’information du patient et de sa compréhension des effets attendus, et de l’expérience du praticien.
Published: 2021

11. Online training on how to diagnose anoperineal lesions of Crohn's disease: Do pictures matter? A nationwide randomized study

Author: Laurent Siproudhis, P. Roumeguère, Paul Benfredj, C. Bord, E. Pommaret, A Nouts, Laurent Abramowitz, Guillaume Bonnaud, Dominique Bouchard, C Geffrier, F Devulder, V. de Parades, J M Didelot, T. Higuero, Ghislain Staumont, Jean-David Zeitoun, Guillaume Bouguen, P Marteau, F. Pigot, X. Lesage, P Petit, Nadia Fathallah, Clinique Beau Soleil [Montpellier], Service de Chirurgie Hépatobiliaire et Digestive [Rennes] = Hepatobiliary and Digestive Surgery [Rennes], CHU Pontchaillou [Rennes], Clinique Saint Augustin, CHU Saint-Antoine [AP-HP], and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)
Subjects: medicine.medical_specialty, [SDV]Life Sciences [q-bio], Perineum, law.invention, Education, Distance, 03 medical and health sciences, 0302 clinical medicine, Crohn Disease, Randomized controlled trial, law, Medical Illustration, Skin Ulcer, Photography, Clinical endpoint, Humans, Rectal Fistula, Medicine, In patient, Anus Diseases, Crohn's disease, Electronic Mail, Hepatology, business.industry, Gastroenterology, medicine.disease, Abscess, 3. Good health, Erythema, 030220 oncology & carcinogenesis, Physical therapy, Online teaching, 030211 gastroenterology & hepatology, Educational Measurement, France, business
Abstract: Summary Any gastroenterologist must be trained to properly diagnose anoperineal lesions in patients with Crohn's disease (APLOC). The aim of this study was to establish whether adding pictures would improve teaching effectiveness of the diagnosis of APLOC to French gastroenterology trainees. Method Trainees were asked to answer a first web-based survey consisting of evaluating 12 pictures of APLOC with a closed answer questionnaire. They were then randomized in 2 groups. Group A received an online teaching with typical pictures and APLOC definitions and group B definitions only. Trainees were asked again seven days later to answer a second survey with 12 other pictures of APLOC and 14 experts also answered this survey. Diagnostic scores were expressed in %. The primary endpoint was the comparison of the score of survey 2 between the two groups of trainees. Secondary endpoints were to compare results of survey 2 between trainees of both groups and experts, and assess diagnosis of each lesion. Results Two hundred fourty eight trainees among 465 answered survey 1, and 195 survey 2. The diagnostic score was 71.9% for groups A and B and 74.6% for experts (differences NS). After training diagnosis of ulceration was 72% for group A and 72.9% for group B, fistulae 85.2% versus 85.8%, erythema 44.1% vs. 55.6%, anoperineal scars 67.5% vs. 65.6%, and abscess 100% (differences NS). Conclusion There was no difference between the two teaching methods. Further research should be performed aiming at improving teaching material and quotation baremes.
Published: 2019

12. A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer

Author: Karin Stinesen Kollberg, Monique J. Roobol, Chris H. Bangma, Vera Nelen, Sigrid Carlsson, Tuomas P. Kilpeläinen, Franz Recker, Ulf Hakan Stenman, Hans Lilja, Rebecka Arnsrud Godtman, Arnauld Villers, Louis Denis, Alvaro Paez, Marcos Lujan, Teuvo L.J. Tammela, Marianne Månsson, Paula Kujala, Marco Zappa, Kirsi Talala, Anssi Auvinen, Kimmo Taari, Andreas R. Huber, Theodorus van der Kwast, Sue Moss, Eveline A.M. Heijnsdijk, Harry J. de Koning, Maciej Kwiatkowski, Xavier Rebillard, Donella Puliti, Fritz H. Schröder, Jonas Hugosson, Urology, Public Health, Clinique Beau Soleil [Montpellier], HUS Abdominal Center, Department of Surgery, Urologian yksikkö, and Clinicum
Subjects: Male, Time Factors, 030232 urology & nephrology, Rate ratio, law.invention, [SHS]Humanities and Social Sciences, Prostate cancer, 0302 clinical medicine, Randomized controlled trial, law, Mass Screening, Early Detection of Cancer, ComputingMilieux_MISCELLANEOUS, RISK, education.field_of_study, Incidence, Prostate Cancer, Incidence (epidemiology), DEATH, Middle Aged, 3. Good health, Europe, ERSPC, Prostate-specific antigen, Italy, 030220 oncology & carcinogenesis, Screening, medicine.medical_specialty, Urology, 3122 Cancers, Population, Article, 03 medical and health sciences, SDG 3 - Good Health and Well-being, Internal medicine, medicine, Humans, education, Update in Urology, Aged, business.industry, MORTALITY, Screening Trial, Prostatic Neoplasms, Prostate-Specific Antigen, 3126 Surgery, anesthesiology, intensive care, radiology, medicine.disease, Confidence interval, business, Follow-Up Studies
Abstract: Background: The European Randomized study of Screening for Prostate Cancer (ERSPC) has previously demonstrated that prostate-specific antigen (PSA) screening decreases prostate cancer (PCa) mortality. Objective: To determine whether PSA screening decreases PCa mortality for up to 16 yr and to assess results following adjustment for nonparticipation and the number of screening rounds attended. Design, setting, and participants: This multicentre population-based randomised screening trial was conducted in eight European countries. Report includes 182 160 men, followed up until 2014 (maximum of 16 yr), with a predefined core age group of 162 389 men (55-69 yr), selected from population registry. Outcome measurements and statistical analysis: The outcome was PCa mortality, also assessed with adjustment for nonparticipation and the number of screening rounds attended. Results and limitations: The rate ratio of PCa mortality was 0.80 (95% confidence interval [CI] 0.72-0.89, p 20 ng/ml (9.9% compared with 4.1% in the second round, p
Published: 2019

13. Fluoxetine for the Symptomatic Treatment of Multiple System Atrophy: The MSA-FLUO Trial

Author: Marc Vérin, Anne Pavy-Le Traon, Vanessa Rousseau, Margherita Fabbri, Alexandra Foubert-Samier, Wassilios G. Meissner, François Tison, Philippe Couratier, Agnès Sommet, Luc Defebvre, Valérie Cochen De Cock, Santiago Perez-Lloret, Franck Durif, Christine Tranchant, Claire Thalamas, Jean-Philippe Azulay, Philippe Remy, Jean-Christophe Corvol, Philippe Damier, Olivier Rascol, Jean-Luc Houeto, Christian Geny, Centre d'investigation clinique de Toulouse (CIC 1436), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-CHU Toulouse [Toulouse]-Institut National de la Santé et de la Recherche Médicale (INSERM), EuroMov - Digital Health in Motion (Euromov DHM), IMT - MINES ALES (IMT - MINES ALES), Institut Mines-Télécom [Paris] (IMT)-Institut Mines-Télécom [Paris] (IMT)-Université de Montpellier (UM), Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM), French-Clinical Research Infrastructure Network - F-CRIN [Paris] (Cardiovascular & Renal Clinical Trialists - CRCT ), CHU Bordeaux [Bordeaux], Bordeaux population health (BPH), Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM), Consejo Nacional de Investigaciones Científicas y Técnicas [Buenos Aires] (CONICET), Hôpital de la Timone [CHU - APHM] (TIMONE), Institut du Cerveau et de la Moëlle Epinière = Brain and Spine Institute (ICM), Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), CHU Limoges, Centre hospitalier universitaire de Nantes (CHU Nantes), Lille Neurosciences & Cognition - U 1172 (LilNCog (ex-JPARC)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), CHU Clermont-Ferrand, Neuro-Psycho Pharmacologie des Systèmes Dopimanégiques sous-corticaux (NPsy-Sydo), CHU Clermont-Ferrand-Université Clermont Auvergne (UCA), Euromov (EuroMov), Université de Montpellier (UM), CHI Créteil, Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), Université de Strasbourg (UNISTRA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Comportement et noyaux gris centraux = Behavior and Basal Ganglia [Rennes], Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Université européenne de Bretagne - European University of Brittany (UEB)-CHU Pontchaillou [Rennes]-Institut des Neurosciences Cliniques de Rennes (INCR), CHU Pontchaillou [Rennes], Institut des Maladies Neurodégénératives [Bordeaux] (IMN), Université de Bordeaux (UB)-Centre National de la Recherche Scientifique (CNRS), NS-Park/FCRIN Network, UMS 015, Centre d’Excellence en Maladies Neurodégénératives (NeuroToul), CHU Toulouse [Toulouse], Clinique Beau Soleil [Montpellier], Pontifical Catholic University of Argentina (UCA), Institut du Cerveau = Paris Brain Institute (ICM), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Hôpital Nord Laennec [CHU Nantes], Lille Neurosciences & Cognition - U 1172 (LilNCog), CHU Lille, CHU Clermont-Ferrand-Université Clermont Auvergne [2017-2020] (UCA [2017-2020]), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), CHU Henri Mondor, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Université de Strasbourg (UNISTRA), Les Hôpitaux Universitaires de Strasbourg (HUS), University of Otago [Dunedin, Nouvelle-Zélande], Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Pôle Santé publique et médecine publique [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Henri Mondor [Créteil], and Université de Rennes (UR)-Université européenne de Bretagne - European University of Brittany (UEB)-CHU Pontchaillou [Rennes]-Institut des Neurosciences Cliniques de Rennes = Institute of Clinical Neurosciences of Rennes (INCR)
Subjects: 0301 basic medicine, medicine.medical_specialty, Serotonin reuptake inhibitor, [SDV]Life Sciences [q-bio], multiple system atrophy, ENSAYO CLINICO, Placebo, law.invention, 03 medical and health sciences, NEUROBIOLOGIA, 0302 clinical medicine, Atrophy, Randomized controlled trial, Double-Blind Method, Rating scale, law, Internal medicine, Surveys and Questionnaires, medicine, ATROFIA MULTISISTÉMICA, Humans, symptomatic treatment, Fluoxetine, business.industry, Beck Depression Inventory, fluoxetine, ENFERMEDADES NEURODEGENERATIVAS, Parkinson Disease, clinical trial, medicine.disease, Confidence interval, 3. Good health, ENFERMEDAD DE PARKINSON, 030104 developmental biology, Treatment Outcome, Neurology, Quality of Life, placebo, TRATAMIENTO MEDICO, Neurology (clinical), business, 030217 neurology & neurosurgery, medicine.drug
Abstract: Fil: Rascol, Olivier. Universidad de Toulouse. Hospital Universitario de Toulouse; Francia Fil: Rascol, Olivier. Centro NeuroToul COEN; Francia Fil: Rascol, Olivier. Clínica de Toulouse. Centro de Investigación. Departamentos de Neurociencias y Farmacología Clínica; Francia Fil: Cochen De Cock, Valérie. Clínica Beau Soleil. Departamento de Neurología; Francia Fil: Cochen De Cock, Valérie. Universidad de Montpellier. EuroMov Digital Health in Motion; Francia Fil: Pavy-Le Traon, Anne. Centro de referencia de atrofia multisistémica; Francia Fil: Pavy-Le Traon, Anne. Universidad de Toulouse. Hospital Universitario de Toulouse. Instituto de Enfermedades Cardiovasculares y Metabólicas. Centro de Investigación Clínica de Toulouse. Departamento de Neurociencias; Francia Fil: Foubert-Samier, Alexandra. Universidad de Toulouse. Hospital Universitario de Toulouse. Instituto de Enfermedades Cardiovasculares y Metabólicas. Departamento de Neurociencias, Centro de investigación Clínica de Toulouse; Francia Fil: Thalamas, Claire. Universidad de Toulouse. Hospital Universitario de Toulouse. Centro de Investigación Clínica de Toulouse; Francia Fil: Thalamas, Claire. Hospital Universitario de Burdeos; Francia Fil: Sommet, Agnès. Red Francesa de Infraestructura de Investigación Clínica; Francia Fil: Pérez Lloret, Santiago. Universidad Abierta Interamericana. Centro de Investigaciones Biomédicas; Argentina Fil: Pérez Lloret, Santiago. Pontificia Universidad Católica Argentina. Facultad de Ciencias Médicas; Argentina Fil: Fabbri, Margherita. Red Francesa de Infraestructura de Investigación Clínica; Francia Fil: Azulay, Jean Philippe. Universidad de Aix-Marsella. Sistema de Hospitales Universitarios Públicos de Marsella; Francia Fil: Corvol, Jean-Christophe. Universidad de la Sorbona; Francia Fil: Corvol, Jean-Christophe. Hospital de la Pitié-Salpêtrière; Francia Fil: Corvol, Jean-Christophe. Red Francesa de Infraestructura de Investigación Clínica; Francia Fil: Couratier, Philippe. Red Francesa de Infraestructura de Investigación Clínica; Francia Fil: Damier, Philippe. Hospital Nord Laennec. Centro de Investigación Clínica; Francia Fil: Defebvre, Luc. Universidad en Lille; Francia Fil: Defebvre, Luc. Hospital Universitario de Marsella. Departamento de Neurología y Patología del Movimiento; Francia Fil: Durif, Franck. Centro Hospitalario Universitario, Clermont-Ferrand. Departamento de Neurología; Francia Fil: Durif, Franck. Red Francesa de Infraestructura de Investigación Clínica; Francia Fil: Geny, Christian. Universidad de Montpellier. Departamento de Neurología; Francia Fil: Houeto, Jean-Luc. Centro Hospitalario Universitario de Limoges; Francia Fil: Houeto, Jean-Luc. Centro de referencia de atrofia multisistémica. Departamento de Neurología. Centro de Expertos en Parkinson; Francia Fil: Rascol, Olivier. Centro de referencia de atrofia multisistémica; Francia Fil: Remy, Philippe. Red Francesa de Infraestructura de Investigación Clínica. Centros Expertos en Parkinson; Francia Fil: Remy, Philippe. Instituto de Investigaciones Biomédicas Mondor; Francia Fil: Tranchant, Christine. Hospital Universitario de Estrasburgo. Red Francesa de Infraestructura de Investigación Clínica. Departamento de Neurología; Francia Fil: Verin, Marc. Universidad de Rennes. Hospital Universitario de Rennes. Red Francesa de Infraestructura de Investigación Clínica. Centro de expertos en Parkinson; Francia Fil: Tison, François. Centro de referencia de atrofia multisistémica. Departamento de Neurología de Enfermedades Neurodegenerativas; Francia Fil: Meissner, Wassilios G. Instituto de Investigación del Cerebro; Nueva Zelanda Fil: Meissner, Wassilios G. Universidad de Otago. Departamento de Medicina; Nueva Zelanda Abstract: Background: There are no effective treatments for multiple system atrophy (MSA). Objective: The objective of this study was to assess the efficacy and safety of the serotonin reuptake inhibitor fluoxetine (40 mg/d) for the symptomatic treatment of MSA. Methods: This was a double-blind, parallel-group, placebo-controlled, randomized trial in patients with "probable" MSA. The primary outcome was the change from baseline to week 12 in the mean total score of the Unified MSA Rating Scale (UMSARS Parts I + II). Secondary outcomes included change from baseline to week 6 in total UMSARS, and change from baseline to week 12 in the Scales for Outcomes in Parkinson Disease-Autonomic Dysfunction, Beck Depression Inventory, and different domains of the MSA-Quality of Life Questionnaire. Exploratory outcomes included change from baseline to week 12 in the UMSARS Parts I and II separately and change from baseline to week 24 in the total UMSARS score. Results: A total of 81 patients were randomly assigned, with no significant difference in the primary outcome (-2.13 units [95% confidence interval, CI, -4.55 to 0.29]; P = 0.08). There was a greater reduction on fluoxetine in the change from baseline to 12-week in UMSARS Part II (exploratory outcome: -1.41 units [95% CI, -2.84; 0.03]; p = 0.05) and in MSA-QoL emotional/social dimension (secondary outcome: -6.99 units [95% CI, -13.40; -0.56]; p < 0.03). A total of 5 deaths occurred (3 on fluoxetine and 2 on placebo). Conclusion: The MSA-FLUO failed to demonstrate fluoxetine superiority over placebo on the total UMSARS score, whereas trends in motor and emotional secondary/exploratory outcomes deserve further investigation.
Published: 2021

14. Le cancer du rein dans le département de L’Hérault : résultats de 30 ans d’enregistrement

Author: D. Azria, Faiza Bessaoud, D. Ayuso, R. Reis Borges, I. Serre, Jean-Pierre Daurès, X. Rebillard, François Iborra, C. Gras, O. Delbos, et tous les acteurs de l’onco-urologie de l’Hérault, J. Bringer, M. Hutin, Brigitte Trétarre, Rodolphe Thuret, D. Brel, Clinique Beau Soleil [Montpellier], Centre hospitalier Intercommunal du Bassin de Thau, Registre des Tumeurs de l'Hérault, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Institut Desbrest de santé publique (IDESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Urodoc [Montpellier], Polyclinique Saint Privat, Centre Hospitalier de Béziers, Institut de Recherche en Cancérologie de Montpellier (IRCM - U1194 Inserm - UM), CRLCC Val d'Aurelle - Paul Lamarque-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Centre de pathologie Biterrois [Bézers], and Inopath Labosud Alco [Montpellier]
Subjects: Gynecology, medicine.medical_specialty, Registry, business.industry, Epidemiology, Urology, Incidence, 030232 urology & nephrology, Mortalité, urologic and male genital diseases, [SDV.MHEP.UN]Life Sciences [q-bio]/Human health and pathology/Urology and Nephrology, female genital diseases and pregnancy complications, Renal cell carcinoma, 3. Good health, Tumeur du rein, Épidémiologie, 03 medical and health sciences, 0302 clinical medicine, Registre, medicine, Mortality, business
Abstract: Resume Objectif L’objectif de cette etude est de presenter l’evolution de l’epidemiologie du cancer du rein dans l’Herault a partir des donnees collectees par le registre des tumeurs de l’Herault (RTH) sur une periode de 30 ans. Materiels et methodes A partir de la base de donnees du RTH, nous avons etudie l’evolution du cancer du rein de 1987 a 2016. Nous avons analyse les donnees concernant l’incidence, la mortalite, l’anatomopathologie des tumeurs et leur stade au diagnostic. Nous avons compare ces resultats aux donnees nationales et internationales. Resultats Nous avons recense 3769 nouveaux cas de cancers du rein: 2628 chez l’homme (69,7 %) et 1141 chez la femme (30,3 %). En 2016, le cancer du rein etait le 8e cancer tous sexes confondus, le 7e cancer chez l’homme et le 11e chez la femme. Entre 1987 et 2016 le nombre de nouveaux cas de cancer du rein a ete multiplie par 4,2 chez l’homme et par 3,3 chez la femme. Le nombre de formes localisees a augmente de 9 % en 20 ans. En 2016 la probabilite, d’etre atteint d’un cancer du rein avant 75 ans est de 2,11 % pour un homme et de 0,62 % pour une femme. Conclusion En 30 ans, l’incidence du cancer du rein a fortement augmente dans l’Herault alors que l’on observe une diminution de sa mortalite. Ces donnees analytiques seront ameliorees par le developpement du Registre de l’Herault Specialise en Onco Urologie (RHESOU) Niveau de preuve 3.
Published: 2021

15. BeatWalk: Personalized Music-Based Gait Rehabilitation in Parkinson’s Disease

Author: Valérie Cochen De Cock, Dobromir Dotov, Loic Damm, Sandy Lacombe, Petra Ihalainen, Marie Christine Picot, Florence Galtier, Cindy Lebrun, Aurélie Giordano, Valérie Driss, Christian Geny, Ainara Garzo, Erik Hernandez, Edith Van Dyck, Marc Leman, Rudi Villing, Benoit G. Bardy, Simone Dalla Bella, EuroMov - Digital Health in Motion (Euromov DHM), IMT - MINES ALES (IMT - MINES ALES), Institut Mines-Télécom [Paris] (IMT)-Institut Mines-Télécom [Paris] (IMT)-Université de Montpellier (UM), Clinique Beau Soleil [Montpellier], McMaster University [Hamilton, Ontario], Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Montpellier, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), AZTI - Tecnalia, Ghent University Hospital, National University of Ireland Maynooth (Maynooth University), International Laboratory for Brain, Music and Sound Research (BRAMS), Université de Montréal (UdeM), Université du Québec à Montréal = University of Québec in Montréal (UQAM), University of Economics and Human Sciences in Warsaw [Varsovie, Pologne], and IMT - Mines Alès, Administrateur
Subjects: 0301 basic medicine, medicine.medical_specialty, Technology and Engineering, [SPI] Engineering Sciences [physics], medicine.medical_treatment, Parkinson's disease, physical activity, gait rehabilitation, Fear of falling, 03 medical and health sciences, [SPI]Engineering Sciences [physics], 0302 clinical medicine, Physical medicine and rehabilitation, Gait (human), Quality of life, medicine, Medicine and Health Sciences, Psychology, rhythmic auditory stimulation, General Psychology, Gait rehabilitation, Original Research, Rehabilitation, business.industry, Physical activity, Usability, Rehabilitation in Parkinson's disease, Arts and Architecture, BF1-990, Rhythmic auditory stimulation, 030104 developmental biology, Duration (music), Cueing, Parkinson’s disease, precision medicine BeatWalk, medicine.symptom, Precision medicine BeatWalk, Cadence, business, human activities, 030217 neurology & neurosurgery, cueing
Abstract: Taking regular walks when living with Parkinson’s disease (PD) has beneficial effects on movement and quality of life. Yet, patients usually show reduced physical activity compared to healthy older adults. Using auditory stimulation such as music can facilitate walking but patients vary significantly in their response. An individualized approach adapting musical tempo to patients’ gait cadence, and capitalizing on these individual differences, is likely to provide a rewarding experience, increasing motivation for walk-in PD. We aim to evaluate the observance, safety, tolerance, usability, and enjoyment of a new smartphone application. It was coupled with wearable sensors (BeatWalk) and delivered individualized musical stimulation for gait auto-rehabilitation at home. Forty-five patients with PD underwent a 1-month, outdoor, uncontrolled gait rehabilitation program, using the BeatWalk application (30 min/day, 5 days/week). The music tempo was being aligned in real-time to patients’ gait cadence in a way that could foster an increase up to +10% of their spontaneous cadence. Open-label evaluation was based on BeatWalk use measures, questionnaires, and a six-minute walk test. Patients used the application 78.8% (±28.2) of the prescribed duration and enjoyed it throughout the program. The application was considered “easy to use” by 75% of the patients. Pain, fatigue, and falls did not increase. Fear of falling decreased and quality of life improved. After the program, patients improved their gait parameters in the six-minute walk test without musical stimulation. BeatWalk is an easy to use, safe, and enjoyable musical application for individualized gait rehabilitation in PD. It increases “walk for exercise” duration thanks to high observance. This research was supported by a European grant: BeatHealth: Health and Wellness on the Beat for VC, DD, CL, AGi, VD, RV, EH, ED, ML, BB, and SB (EU FP7-ICT contract #610633).
Published: 2021

16. Comprehensive Analysis of Familial Parkinsonism Genes in Rapid‐Eye‐Movement Sleep Behavior Disorder

Author: Christelle Charley Monaca, Alex Desautels, Yves Dauvilliers, Beatriz Abril, Elena Antelmi, Ambra Stefani, Giuseppe Plazzi, Karel Sonka, Monica Puligheddu, Brit Mollenhauer, Birgit Högl, Sandra B. Laurent, Eric Yu, Farnaz Asayesh, Luigi Ferini-Strambi, Mariarosaria Valente, Jennifer A. Ruskey, Michela Figorilli, Uladzislau Rudakou, Annette Janzen, Ziv Gan-Or, Francesco Janes, Mineke Viaene, Ronald B. Postuma, Valérie Cochen De Cock, Bradley F. Boeve, David Kemlink, Evi Holzknecht, Dan Spiegelman, Jacques Montplaisir, Anna Heidbreder, Gian Luigi Gigli, Michele T.M. Hu, Friederike Sixel-Döring, Lynne Krohn, Kheireddin Mufti, Guy A. Rouleau, Isabelle Arnulf, Claudia Trenkwalder, Wolfgang H. Oertel, Femke Dijkstra, Jean-François Gagnon, Centre de Recherche de l'Institut du Cerveau et de la Moelle épinière (CRICM), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Hôpital Gui de Chauliac [CHU Montpellier], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Clinique Beau Soleil [Montpellier], EuroMov - Digital Health in Motion (Euromov DHM), IMT - MINES ALES (IMT - MINES ALES), Institut Mines-Télécom [Paris] (IMT)-Institut Mines-Télécom [Paris] (IMT)-Université de Montpellier (UM), CHU Lille, Université de Lille, Hôpital Universitaire Carémeau [Nîmes] (CHU Nîmes), Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), Mufti, K., Rudakou, U., Yu, E., Krohn, L., Ruskey, J. A., Asayesh, F., Laurent, S. B., Spiegelman, D., Arnulf, I., M. T. M., Hu, Montplaisir, J. Y., Gagnon, J. -F., Desautels, A., Dauvilliers, Y., Gigli, G. L., Valente, M., Janes, F., Hogl, B., Stefani, A., Holzknecht, E., Sonka, K., Kemlink, D., Oertel, W., Janzen, A., Plazzi, G., Antelmi, E., Figorilli, M., Puligheddu, M., Mollenhauer, B., Trenkwalder, C., Sixel-Doring, F., Cochen De Cock, V., Monaca, C. C., Heidbreder, A., Ferini-Strambi, L., Dijkstra, F., Viaene, M., Abril, B., Boeve, B. F., Postuma, R. B., Rouleau, G. A., and Gan-Or, Z.
Subjects: 0301 basic medicine, Heterozygote, Parkinson's disease, MESH: Sleep, [SDV]Life Sciences [q-bio], REM sleep behavior disorder, Rapid eye movement sleep, Disease, genetic analysis, Compound heterozygosity, Genetic analysis, 03 medical and health sciences, 0302 clinical medicine, Parkinsonian Disorders, Medicine, Humans, MESH: Heterozygote, Genetics, MESH: Humans, business.industry, MESH: Parkinsonian Disorders, PARK7, Parkinson Disease, medicine.disease, LRRK2, 3. Good health, 030104 developmental biology, Neurology, MESH: REM Sleep Behavior Disorder, Human medicine, Neurology (clinical), business, Sleep, 030217 neurology & neurosurgery, MESH: Parkinson Disease
Abstract: International audience; Background: There is only partial overlap in the genetic background of isolated rapid-eye-movement sleep behavior disorder (iRBD) and Parkinson's disease (PD).Objective: To examine the role of autosomal dominant and recessive PD or atypical parkinsonism genes in the risk of iRBD.Methods: Ten genes, comprising the recessive genes PRKN, DJ-1 (PARK7), PINK1, VPS13C, ATP13A2, FBXO7, and PLA2G6 and the dominant genes LRRK2, GCH1, and VPS35, were fully sequenced in 1039 iRBD patients and 1852 controls of European ancestry, followed by association tests.Results: We found no association between rare heterozygous variants in the tested genes and risk of iRBD. Several homozygous and compound heterozygous carriers were identified, yet there was no overrepresentation in iRBD patients versus controls.Conclusion: Our results do not support a major role for variants in these genes in the risk of iRBD. © 2020 International Parkinson and Movement Disorder Society.
Published: 2021

17. Biothérapies pour les troubles de l’érection et la maladie de la Peyronie : ou en est-on ?

Author: E. Huyghe, D. Carnicelli, F.X. Madec, C. Methorst, R. Yiou, Jean-Etienne Terrier, A. Schirmann, François Marcelli, L. Ferretti, K. Ben-Naoum, J.-P. Graziana, V. Hupertan, N. Morel-Journel, W. Akakpo, L. Savareux, A. Faix, Service d'Urologie [CHU Pitié-Salpêtrière], CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Hôpital d'Instruction des Armées Robert Picqué, Service de Santé des Armées, Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), Service d'urologie, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Clinique Beau Soleil [Montpellier], and Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-IFR10
Subjects: Gynecology, medicine.medical_specialty, Stem cell, business.industry, Biotherapy, Urology, Peyronie's disease, [SDV]Life Sciences [q-bio], 030232 urology & nephrology, Maladie de la Peyronie, Cell therapy, Dysfonction érectile, 3. Good health, 03 medical and health sciences, 0302 clinical medicine, Biothérapie, Platelet-rich plasma, Cellules souches, medicine, Erectile dysfunction, Plasma enrichi en plaquettes, business, Thérapie cellulaire
Abstract: Resume Contexte Des essais cliniques de therapie cellulaire ont recemment ete conduits pour la dysfonction erectile (DE) et la maladie de la Peyronie apres une phase de recherche fondamentale. Objectifs Mise au point sur les biotherapies de la DE et de la maladie de la Peyronie, et description du cadre reglementaire regissant ces nouvelles strategies therapeutiques. Sources documentaires Revue de la litterature sur PubMed et Clinical.trials.gov avec les principaux mots-clefs suivants : « erectile dysfunction », « Peyronie's disease », « stem cell », et « platelet-rich plasma ». Resultats et limites La recherche fondamentale a montre la possibilite d’ameliorer la fonction erectile dans des modeles murins de DE post-prostatectomie radicale ou metabolique. Les sources biologiques testees sont la moelle osseuse, le tissus adipeux et le sang (PRP, plasma riche en plaquette). Le mode d’action de ces biotherapies est probablement temporaire et principalement de nature paracrine. Quatre essais cliniques ont ete publies dans le cadre de la DE post-prostatectomie radicale ou chez des patients diabetiques, et 1 autre pour la maladie de la Peyronie. Onze essais cliniques dont trois randomises sont en cours pour les DE organiques. Les premiers resultats suggerent la possibilite d’ameliorer la fonction erectile spontanee et la reponse au traitement medical (chez des patients initialement non repondeurs) via une amelioration de la vascularisation penienne. Une reduction de la courbure penienne a ete notee apres injection cellulaire dans la plaque de la Peyronie. Aucun effet secondaire n’a ete rapporte. La plupart des procedes testes sont considerees comme des « medicaments de therapie innovante » avec des contraintes reglementaires lourdes, notamment s’il existe une modification « substantielle » des cellules. Pour les procedures de biotherapie extemporanee, sans modification substantielle et utilisant un tissu homologue, la qualification reglementaire reste floue et beaucoup plus permissive. Conclusion Les premiers resultats cliniques de biotherapie pour DE sont prometteurs. Le cadre reglementaire peut varier considerablement selon le mode de preparation des cellules a injecter et leur origine, generant ainsi des contraintes radicalement differentes pour un meme effet recherche. Cet aspect reglementaire est un facteur decisif a prendre en compte pour le choix de la procedure.
Published: 2020

18. Le cancer de la vessie dans le département de l’Hérault : résultats de 30 ans d’enregistrement du Registre des Tumeurs de l’Hérault (1987–2016)

Author: Jean-Pierre Daurès, O. Riou, François Iborra, D. Azria, E. Bruneaux, O. Delbos, S. Abdel-Hamid, Rodolphe Thuret, J. Bringer, Brigitte Trétarre, D. Rizet, X. Rebillard, D. Ayuso, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Registre des Tumeurs de l'Hérault, Aide à la Décision pour une Médecine Personnalisé - Laboratoire de Biostatistique, Epidémiologie et Recherche Clinique - EA 2415 (AIDMP), Université Montpellier 1 (UM1)-Université de Montpellier (UM), Clinique Beau Soleil [Montpellier], Polyclinique Saint Privat, CRP Clinique du Parc, Castelnau-Le-Lez, Clinique Saint-Jean - Sud de France [Montpellier], Clinique du Millénaire - Oc Santé [Montpellier], Oc Santé [Montpellier], Hôpitaux du Bassin de Thau (Sète), Institut du Cancer de Montpellier (ICM), Institut de Recherche en Cancérologie de Montpellier (IRCM - U1194 Inserm - UM), CRLCC Val d'Aurelle - Paul Lamarque-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), and Université de Montpellier (UM)
Subjects: 03 medical and health sciences, 0302 clinical medicine, business.industry, 030220 oncology & carcinogenesis, Urology, 030232 urology & nephrology, Medicine, business, Humanities, [SDV.MHEP.UN]Life Sciences [q-bio]/Human health and pathology/Urology and Nephrology, 3. Good health
Abstract: Objectifs Le registre des tumeurs de l’Herault (RTH) est un registre general qualifie par le comite national des registres depuis 1987. L’objectif de cette etude est de presenter l’evolution de l’epidemiologie du cancer de la vessie dans le departement de l’Herault a partir des donnees collectees par le RTH sur une periode de 30 ans. Methodes A partir de la base de donnees du RTH, nous avons etudie l’incidence, les taux d’incidence standardises sur la population mondiale (TSM), la frequence relative, le sex-ratio, l’âge moyen au diagnostic, les donnees anatomopathologiques et les primo-traitements pour toutes les tumeurs de la vessie ≥ T1 dans la population de l’Herault entre 1987 et 2016. Les donnees de mortalite proviennent du service SC8 de l’INSERM (CepiDC). Nous avons compare ces resultats aux donnees nationales et internationales. Les estimations francaises proviennent des donnees FRANCIM et les donnees mondiales des registres sont regroupees par le Centre international de recherche sur le cancer (CIRC), situe a Lyon. Resultats Les TSM du cancer de la vessie pour 100 000 sont passes de 11,1 en 1987–1988 (21 hommes, 3,1 femmes) a 8,2 en 2015–2016 (15,2 hommes, 2,5 femmes). Sur 30 ans, le RTH a recense 5580 cas et 2718 deces. Le rapport mortalite/incidence etait de 48,7 % (45,9 % chez l’homme, 62,1 % chez la femme) et le sex-ratio etait de 4,7 hommes pour une femme. En 2016, il etait le 7e cancer dans l’Herault (5e chez l’homme). Les carcinomes urotheliaux representaient 91,7 % des cancers. En 2016, l’âge moyen au diagnostic etait de 74,8 ans (74,2 ans chez l’homme, 76,9 ans chez la femme) et la probabilite d’avoir un cancer de la vessie avant l’âge de 75 ans etait de 1,81 % pour un homme (1/55) et 0,26 % pour une femme (1/382) ( Fig. 1 ). Discussion L’incidence des tumeurs de la vessie a faiblement diminue chez l’homme dans l’Herault. Les registres ne recueillent que les tumeurs ≥ T1, ce qui differe des recommandations cliniques. En 2018, le Registre de l’Herault Specialise en Onco-Urologie (RHESOU) a vu le jour, dans le but d’apporter plus de coherence entre les donnees epidemiologiques et la pratique clinique actuelle. Conclusion L’incidence des tumeurs de la vessie a faiblement diminue chez l’homme dans l’Herault. Les registres ne recueillent que les tumeurs ≥ T1, ce qui differe des recommandations cliniques. En 2018, le Registre de l’Herault Specialise en Onco-Urologie (RHESOU) a vu le jour, dans le but d’apporter plus de coherence entre les donnees epidemiologiques et la pratique clinique actuelle.
Published: 2020

19. Epidemiology of metastatic castration-resistant prostate cancer: A first estimate of incidence and prevalence using the French nationwide healthcare database

Author: Sylvestre Le Moulec, Nicholas Moore, Marie Pierrès, Patrick Blin, Marine Gross-Goupil, Mathieu Roumiguié, N. Thurin, Magali Rouyer, Jérémy Jové, Cécile Droz-Perroteau, Camille Capone, Xavier Rebillard, Emmanuelle Bignon, Stéphanie Lamarque, Michel Soulié, T. Haaser, CIC Bordeaux, Université Bordeaux Segalen - Bordeaux 2-Institut National de la Santé et de la Recherche Médicale (INSERM), Bordeaux population health (BPH), Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital Saint-André, Clinique Beau Soleil [Montpellier], Hôpital de Rangueil, CHU Toulouse [Toulouse], Hôpital Haut-Lévêque [CHU Bordeaux], CHU Bordeaux [Bordeaux], Service d'Oncologie [Pau], Clinique Marzet [Pau], Janssen-Cilag [Issy-les-Moulineaux], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), and ONOFRE, Mélanie
Subjects: Male, Cancer Research, Databases, Factual, Epidemiology, [SDV.MHEP.UN]Life Sciences [q-bio]/Human health and pathology/Urology and Nephrology, Management of prostate cancer, Prostate cancer, 0302 clinical medicine, Castration Resistance, Health care, Prevalence, 030212 general & internal medicine, Castration-resistant, education.field_of_study, Incidence (epidemiology), Incidence, Healthcare, Validation study, Pharmacoepidemiology, Middle Aged, 3. Good health, Prostatic Neoplasms, Castration-Resistant, Oncology, 030220 oncology & carcinogenesis, France, Prostatic neoplasms, medicine.medical_specialty, Neoplasm metastasis, Population, [SDV.CAN]Life Sciences [q-bio]/Cancer, Database, 03 medical and health sciences, [SDV.CAN] Life Sciences [q-bio]/Cancer, Epidemiology Incidence, medicine, Humans, education, PharmacoEpi-Drugs, business.industry, medicine.disease, [SDV.MHEP.UN] Life Sciences [q-bio]/Human health and pathology/Urology and Nephrology, Cross-Sectional Studies, [SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie, Administrative claims, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, business, Demography
Abstract: International audience; Background: There is a lack of information about the burden of metastatic castration-resistant prostate cancer (mCRPC). The present work aims to estimate the incidence and prevalence of mCRPC in 2014 using the French nationwide healthcare database (SNDS).Methods: Prevalence and incidence were estimated based on an SNDS extraction of men covered by the general healthcare insurance (86 % of the French population), and aged ≥40. Patients with mCRPC were identified amongst prostate cancer cases using an algorithm estimating a date of first metastasis management and a date of castration resistance. This algorithm was validated by clinical experts through a blind review of 200 anonymized medical charts from SNDS data. Prevalence and incidence were standardized on the European Standard Population (2013 edition).Results: Prevalence and incidence of mCRPC were estimated as, respectively, 62 and 21 cases per 100 000 men in 2014. Less than one mCRPC case per 100 000 was observed in men aged 40-49. Maximum mCRPC incidence was in men aged 80-89 (175 per 100 000). The algorithm used for mCRPC identification had 97 % positive and 99 % negative predictive values.Conclusion: The good performances of the algorithm for mCRPC identification and the consistency of the generated results with the existing data highlight the robustness of these first estimates of mCRPC prevalence and incidence. Future updates will call for algorithm adjustment as practices evolve over time. These first real-life data will serve for future follow-up of the impact of changes in the management of prostate cancer.
Published: 2020

20. Impact on quality of life 3 years after diagnosis of prostate cancer patients below 75 at diagnosis: an observational case-control study

Author: Xavier Rebillard, Nadine Houede, Sophie Bouvet, Brigitte Trétarre, Florence Menegaux, Sarah Kabani, Pascale Fabbro-Peray, Institut de Recherche en Cancérologie de Montpellier (IRCM - U1194 Inserm - UM), CRLCC Val d'Aurelle - Paul Lamarque-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Clinique Beau Soleil [Montpellier], Laboratoire de Biostatistique, Epidémiologie clinique, Santé Publique Innovation et Méthodologie [CHU Nîmes] (BESPIM), Hôpital Universitaire Carémeau [Nîmes] (CHU Nîmes), Centre Hospitalier Universitaire de Nîmes (CHU Nîmes)-Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), Institut du Cancer de Montpellier (ICM), Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, and ONOFRE, Mélanie
Subjects: Extracorporeal Shockwave Therapy, Male, 0301 basic medicine, Cancer Research, Time Factors, medicine.medical_treatment, [SDV.MHEP.UN]Life Sciences [q-bio]/Human health and pathology/Urology and Nephrology, Cohort Studies, Androgen deprivation therapy, Prostate cancer, 0302 clinical medicine, Erectile Dysfunction, Quality of life, Surveys and Questionnaires, Prospective Studies, Side effects, Prostatectomy, Middle Aged, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, 3. Good health, Long term survival, Oncology, 030220 oncology & carcinogenesis, Cohort, Urinary dysfunction, Research Article, medicine.medical_specialty, Brachytherapy, Antineoplastic Agents, [SDV.CAN]Life Sciences [q-bio]/Cancer, lcsh:RC254-282, 03 medical and health sciences, [SDV.CAN] Life Sciences [q-bio]/Cancer, Internal medicine, Genetics, medicine, Humans, Watchful Waiting, Aged, Radiotherapy, business.industry, Prostatic Neoplasms, Androgen Antagonists, medicine.disease, Health Surveys, [SDV.MHEP.UN] Life Sciences [q-bio]/Human health and pathology/Urology and Nephrology, 030104 developmental biology, Erectile dysfunction, [SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie, Case-Control Studies, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, business, Sexual function
Abstract: Background Prostate cancer patients are known to suffer from poor sexual and urinary long-term side-effects following treatment, potentially impacting quality of life. The purpose of our study was to compare health-related quality of life at 3 years between prostate cancer patients and healthy controls according to key life-style characteristics. Secondary objectives were to compare urological dysfunction, sexual function, anxiety and depression. Methods Multicentric, case-control, observational prospective, open, follow-up study including 819 prostate cancer patients Results In total, 564 participants were included (mean age 67.9 years): 376 patients and 188 controls. Treatment breakdown was: 258 underwent RP, 90 received EBRT, 52 brachytherapy or HIFU, 15 CT, 26 ADT and 61 AS. There was no difference in median global quality of life between patients and controls (94.87 vs 94.15, p = 0.71). Multivariate analysis showed poorer social functioning in patients (24.3% vs. 16.3%, p = 0.0209), more dyspnea (22% vs. 12.4%, p = 0.0078), and yet less current pain (23% vs 33%, p = 0.0151). Conclusions Global health status score at 3 years after diagnosis was similar between patients and controls, though patients showed a significantly worse social functioning. Prostate cancer diagnosis per se does not seem to impact the quality of life of patients Trial registration clinicaltrials.gov, NCT02854982. Registered 4 August 2016, retrospectively registered.
Published: 2020

21. Is current age related macular degeneration self-monitoring a good tool for detecting exudative recurrence?

Author: C. Chamard, S. Lacombe, S. Allieu, S. Navarre, J.-P. Daures, C. Rohart, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), and Clinique Beau Soleil [Montpellier]
Subjects: Male, medicine.medical_specialty, Current age, Visual acuity, [SDV]Life Sciences [q-bio], Sensitivity and Specificity, Loading dose, Diagnostic Self Evaluation, Macular Degeneration, 03 medical and health sciences, 0302 clinical medicine, Recurrence, Interquartile range, Internal medicine, medicine, Humans, 10. No inequality, Aged, Monitoring, Physiologic, Aged, 80 and over, Amsler grid, business.industry, Exudates and Transudates, Macular degeneration, medicine.disease, Self Efficacy, Confidence interval, 3. Good health, Self Care, Ophthalmology, Cross-Sectional Studies, Wet Macular Degeneration, 030221 ophthalmology & optometry, Female, Observational study, France, medicine.symptom, business
Abstract: Summary Purpose To assess the ability of patients with exudative AMD to detect exudative recurrence. Another objective was to assess if self-monitoring, as currently taught, improves this ability. Materials and methods An observational cross-sectional study was carried out in the ophthalmology center of BeauSoleil clinic in Montpellier between March 1 and April 1 2016. Inclusion criteria were presence of neovascular age related macular degeneration treated with the loading dose of three monthly intravitreal anti-VEGF injections, with at least one injection in the past 12 months and at least one exudative recurrence. All patients underwent a visual acuity measurement with ETDRS charts at 4 meters. A questionnaire assessed familiarity with the Amsler grid and its proper use, performance of and type of self-monitoring at home and the subjective feeling of an exudative recurrence at the visit with a 5-level Likert scale. Results A total of 94 eyes of 70 patients were included in this study with 69.0 % women and a median (interquartile range) age of 83 (77–96) years. Among them, 81 % performed regular self-monitoring, mostly with environmental Amsler tests (70 %). Only 63 % of the patients knew of the Amsler grid, among which 52 % used it correctly. Sensitivity (95 % confidence interval, 95 % CI) and specificity (95 % CI) of the subjective sensation of exudative recurrence were 0.32 (0.14-0.55) and 0.85 (0.74-0.92), respectively, for the entire population. Sensitivity (95 % CI) and specificity (95 % CI) were 0.33 (0.13-0.59) and 0.85 (0.74-0.93); 0.25 (0.0063-0.81) and 0.82 (0.48-0.98), respectively, in patients performing and not performing self-monitoring. Conclusion Patients’ prediction in wet AMD is insufficient in detecting exudative recurrences, even if regular self-monitoring with Amsler grid or environmental Amsler is performed.
Published: 2019

22. LRRK2 protective haplotype and full sequencing study in REM sleep behavior disorder

Author: Peter Young, Birgit Högl, Wolfgang H. Oertel, Michele T.M. Hu, Giuseppe Plazzi, Valérie Cochen De Cock, Dan Spiegelman, Yves Dauvilliers, Elena Antelmi, Jacques Montplaisir, Ambra Stefani, Friederike Sixel-Döring, Jennifer A. Ruskey, Christelle Charley Monaca, Brit Mollenhauer, Ziv Gan-Or, Isabelle Arnulf, Guy A. Rouleau, Ronald B. Postuma, Bouchra Ouled Amar Bencheikh, Claudia Trenkwalder, Luigi Ferini-Strambi, Jean-François Gagnon, Anna Heidbreder, Ouled Amar Bencheikh, Bouchra, Ruskey, Jennifer A., Arnulf, Isabelle, Dauvilliers, Yve, Monaca, Christelle Charley, De Cock, Valérie Cochen, Gagnon, Jean-Françoi, Spiegelman, Dan, Hu, Michele T.M., Högl, Birgit, Stefani, Ambra, Ferini-Strambi, Luigi, Plazzi, Giuseppe, Antelmi, Elena, Young, Peter, Heidbreder, Anna, Mollenhauer, Brit, Sixel-Döring, Friederike, Trenkwalder, Claudia, Oertel, Wolfgang, Montplaisir, Jacques Y., Postuma, Ronald B., Rouleau, Guy A., Gan-Or, Ziv, Ouled Amar Bencheikh, B., Ruskey, J. A., Arnulf, I., Dauvilliers, Y., Monaca, C. C., De Cock, V. C., Gagnon, J. -F., Spiegelman, D., M. T. M., Hu, Hogl, B., Stefani, A., Ferini-Strambi, L., Plazzi, G., Antelmi, E., Young, P., Heidbreder, A., Mollenhauer, B., Sixel-Doring, F., Trenkwalder, C., Oertel, W., Montplaisir, J. Y., Postuma, R. B., Rouleau, G. A., Gan-Or, Z., Service des Pathologies du sommeil [CHU Pitié-Salpêtrière], CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Institut du Cerveau et de la Moëlle Epinière = Brain and Spine Institute (ICM), Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Département de neurologie [Montpellier], Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Hôpital Gui de Chauliac [Montpellier]-Université de Montpellier (UM), Neuropsychiatrie : recherche épidémiologique et clinique (PSNREC), Université Montpellier 1 (UM1)-Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de neurophysiologie clinique (CHRU Lille), Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Euromov (EuroMov), Université de Montpellier (UM), and Clinique Beau Soleil [Montpellier]
Subjects: Male, 0301 basic medicine, REM sleep behavior disorder, Disease, Biology, Leucine-Rich Repeat Serine-Threonine Protein Kinase-2, 03 medical and health sciences, 0302 clinical medicine, Atrophy, Genetic, Genetics, medicine, LRRK2, Parkinson disease, Neurology, Geriatrics and Gerontology, Neurology (clinical), Humans, Coding region, Dementia, Aged, Synucleinopathies, Haplotype, High-Throughput Nucleotide Sequencing, Sequence Analysis, DNA, Middle Aged, Protective Factors, medicine.disease, 3. Good health, 030104 developmental biology, Haplotypes, [SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC], Female, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology, 030217 neurology & neurosurgery
Abstract: Background: Individuals with rapid eye movement (REM)-sleep behavior disorder (RBD) are likely to progress to synucleinopathies, mainly Parkinson's disease (PD), dementia with Lewy-bodies (DLB) and multiple system atrophy (MSA). The genetics of RBD only partially overlaps with PD and DLB, and the role of LRRK2 variants in risk for RBD is still not clear.Methods: The full coding sequence, exon-intron boundaries and 5′ and 3′ untranslated regions of LRRK2 were sequenced using targeted next-generation sequencing. A total of 350 RBD patients and 869 controls were sequenced, and regression and burden models were used to examine the association between LRRK2 variants and RBD.Results: No pathogenic mutations that are known to cause PD were identified in RBD patients. The p.N551K-p.R1398H-p.K1423K haplotype was associated with a reduced risk for RBD (OR = 0.66, 95% CI 0.44–0.98, p = 0.0055 for the tagging p.N551K substitution). A common variant, p.S1647T, was nominally associated with risk for RBD (OR = 1.28, 95% CI 1.05–1.56, p = 0.029). Burden analysis identified associations with domains and exons that were derived by the variants of the protective haplotype, and no burden of other rare variants was identified.Conclusions: Carriers of the LRRK2 p.N551K-p.R1398H-p.K1423K haplotype have a reduced risk for developing RBD, yet PD-causing mutations probably have minor or no role in RBD. Additional work is needed to confirm these results and to identify the mechanism associated with reduced risk for RBD.
Published: 2018

23. Perioperative and economic analysis of surgical treatments for benign prostatic hyperplasia: A study of the French committee on LUT

Author: Nicolas Barry Delongchamps, A. Benchikh, A. De La Taille, Romain Mathieu, Jean-Nicolas Cornu, Vincent Misrai, A. Faix, Grégoire Robert, S. Lebdai, A.R. Azzouzi, Marc Fourmarier, Bertrand Lukacs, A. Descazeaud, O. Dumonceau, Olivier Haillot, CHU Pontchaillou [Rennes], Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM), Service d'urologie [Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Nutrition, inflammation et dysfonctionnement de l'axe intestin-cerveau (ADEN), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institute for Research and Innovation in Biomedicine (IRIB), Normandie Université (NU)-Normandie Université (NU)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM), UNIROUEN - UFR Santé (UNIROUEN UFR Santé), Normandie Université (NU)-Normandie Université (NU), AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service d'urologie [CHU Cochin], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin [AP-HP], Clinique Turin, Clinique Beau Soleil [Montpellier], Centre Hospitalier d'Aix en Provence [Aix-en-Provence] (CHIAP ), Service d'urologie [Tours], Centre Hospitalier Régional Universitaire de Tours (CHRU Tours)-Hôpital Bretonneau, Service d'urologie [CHU Tenon], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Tenon [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Clinique Pasteur [Toulouse], CHU Henri Mondor, service d'urologie [CHU Bordeaux], CHU Bordeaux [Bordeaux], Service de Chirurgie urologique et andrologie [CHU Limoges], and CHU Limoges
Subjects: Male, medicine.medical_specialty, Urology, medicine.medical_treatment, Enucleation, Prostatic Hyperplasia, Open prostatectomy, 030232 urology & nephrology, Photovaporisation prostatique, urologic and male genital diseases, [SDV.MHEP.UN]Life Sciences [q-bio]/Human health and pathology/Urology and Nephrology, Perioperative Care, 03 medical and health sciences, 0302 clinical medicine, Analyse des coûts, Photoselective vaporization of the prostate, Prostate, Holmium laser enucleation, Cost analysis, Humans, Economic analysis, Medicine, Aged, Retrospective Studies, Adénomectomie voie haute, Transurethral resection of the prostate, Prostatectomy, Benign prostatic hyperplasia, business.industry, technology, industry, and agriculture, Résection transurétrale de la prostate, Perioperative, Hyperplasia, medicine.disease, medicine.anatomical_structure, MESH: Prostatectomy/economics, Prostatectomy/methods, Prostatic Hyperplasia/economics, Prostatic Hyperplasia/surgery, 030220 oncology & carcinogenesis, Hypertrophie bénigne de prostate, Cost-minimization analysis, Costs and Cost Analysis, France, Énucléation au laser holmium/thullium, business, Open Prostatectomy
Abstract: International audience; PURPOSE:To evaluate perioperative cost related to surgical treatments of benign prostatic obstruction (BPO): photoselective vaporization of the prostate (pvp), holmium/thullium laser enucleation (HoLEP/ThuLEP), transurethral resection of the prostate (TURP) and open prostatectomy (OP).MATERIAL AND METHODS:We retrospectively collected data from 237 patients who consecutively underwent a surgical treatment for BPH between January 2012 and June 2013 at nine institutions in France. An economic simulation model was constructed to estimate the cost of hospitalization related to surgical procedure from the hospital perspective and a cost minimization analysis was performed.RESULTS:TURP, OP, HoLEP/ThuLEP and PVP were performed in 99 (42%), 23 (10%), 64 (27%) and 51 (21%) patients, respectively. For men with prostate size
Published: 2017

24. Prostatectomie radicale laparoscopique robot-assistée : quelles sont les preuves à l’heure d’une demande de nomenclature spécifique ?

Author: X. Rébillard, G. Poinas, G. Fiard, J.-L. Descotes, M. Leprêtre, C. Delaitre-Bonnin, J.-A. Long, Centre Hospitalier Universitaire [Grenoble] (CHU), Gestes Medico-chirurgicaux Assistés par Ordinateur (TIMC-IMAG-GMCAO), Techniques de l'Ingénierie Médicale et de la Complexité - Informatique, Mathématiques et Applications, Grenoble - UMR 5525 (TIMC-IMAG), Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019])-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019]), Clinique Beau Soleil [Montpellier], Service d'urologie, CHU Grenoble-Hôpital Michallon, Ecosystèmes Insulaires Océaniens (UMR 241) (EIO), Université de la Polynésie Française (UPF)-Institut Louis Malardé [Papeete] (ILM), Institut de Recherche pour le Développement (IRD)-Institut de Recherche pour le Développement (IRD)-Institut Français de Recherche pour l'Exploitation de la Mer (IFREMER), Mapi Group, Institut des Biomolécules Max Mousseron [Pôle Chimie Balard] (IBMM), Centre National de la Recherche Scientifique (CNRS)-Institut de Chimie du CNRS (INC)-Université de Montpellier (UM)-Ecole Nationale Supérieure de Chimie de Montpellier (ENSCM), and Association Française d'Urologie
Subjects: Gynecology, medicine.medical_specialty, Prostate cancer, business.industry, Prostatectomie radicale, [SDV]Life Sciences [q-bio], Urology, 030232 urology & nephrology, Robotics, Functional outcomes, Radical prostatectomy, Résultats oncologiques, 03 medical and health sciences, 0302 clinical medicine, 030220 oncology & carcinogenesis, Oncological outcomes, Medicine, Robotique, Cancer de prostate, business, Résultats fonctionnels
Abstract: Resume Introduction Malgre une diminution du nombre de prostatectomies totales en France, la proportion de prostatectomies assistees par robot augmente. L’objectif de ce travail est de faire une mise au point comparant les resultats de la prostatectomie robot-assistee avec ceux des voies d’abord ouverte et cœlioscopique. Materiel et methodes Une revue systematique de la litterature sur PubMed a ete effectuee. Les etudes prospectives ainsi que les meta-analyses comparant prostatectomie totale robot-assistee (PTAR), laparoscopique (PTL) et par chirurgie ouverte (PTCO) ont ete retenues. Resultats La fonction erectile etait significativement meilleure apres PTAR qu’apres PTL. Comparativement a la PTCO, la sexualite etait d’apres des meta-analyses, significativement meilleure a 12 mois et le risque absolu de dysfonction erectile significativement diminue. La continence apres PTAR etait significativement meilleure, et des 3 mois, qu’apres PTL. Comparativement a la PTCO, le taux de patients continents etait discordant, tantot significativement meilleurs pour la PTAR, tantot sans difference. Le taux de marges positives etait similaire entre les techniques de PTAR, PTL et PTCO. Le suivi a long terme montrait des resultats equivalents sous reserve d’un recul insuffisant. En termes de complications peri-operatoires, aucune difference significative n’a ete observee entre la PTAR comparativement a la de PTL ou PTCO. Conclusion La PTAR offre les memes garanties oncologiques que les voies ouvertes et laparoscopique. La continence et la sexualite sont meilleures qu’en laparoscopie et par voie ouverte. Il n’existe toutefois pas d’etude randomisee a long terme comparant PTAR et PTCO. Ces donnees sont importantes a connaitre pour justifier d’un codage specifique CCAM.
Published: 2017

25. Tumeurs testiculaires dans le département de l’Hérault : résultats de 30 ans d’enregistrement (1987–2016)

Author: D. Rizet, O. Delbos, Thibaut Murez, D. Ayuso, Brigitte Trétarre, G. Poinas, François Iborra, J. Bringer, S. Abdel-Hamid, D. Azria, Rodolphe Thuret, X. Rebillard, Clinique Beau Soleil [Montpellier], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Registre des Tumeurs de l'Hérault, Aide à la Décision pour une Médecine Personnalisé - Laboratoire de Biostatistique, Epidémiologie et Recherche Clinique - EA 2415 (AIDMP), Université Montpellier 1 (UM1)-Université de Montpellier (UM), Université de Montpellier (UM), CRP Clinique du Parc, Castelnau-Le-Lez, Clinique du Millénaire - Oc Santé [Montpellier], Oc Santé [Montpellier], Clinique Saint-Jean - Sud de France [Montpellier], Hôpitaux du Bassin de Thau (Sète), Polyclinique Saint Privat, Institut du Cancer de Montpellier (ICM), Institut de Recherche en Cancérologie de Montpellier (IRCM - U1194 Inserm - UM), and CRLCC Val d'Aurelle - Paul Lamarque-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)
Subjects: 03 medical and health sciences, 0302 clinical medicine, business.industry, 030220 oncology & carcinogenesis, Urology, 030232 urology & nephrology, Medicine, business, [SDV.MHEP.UN]Life Sciences [q-bio]/Human health and pathology/Urology and Nephrology, Humanities, 3. Good health
Abstract: International audience; ObjectifsLe registre des tumeurs de l’Hérault est un registre général qualifié par le comité national des registres depuis 1987. L’objectif de cette étude est de présenter l’évolution de l’épidémiologie des cancers testiculaires dans le département de l’Hérault à partir des données collectées par le registre des tumeurs de l’Hérault (RTH) sur une période de 30 ans.MéthodesÀ partir de la base de données du RTH, nous avons étudié l’évolution des tumeurs de la vessie de 1987 à 2016. Nous avons analysé les données concernant l’incidence, la mortalité, l’anatomopathologie des tumeurs et leur stade au diagnostic. Nous avons comparé ces résultats aux données nationales et internationales.RésultatsNous avons recensé 729 nouveaux cas de tumeur du testicule. Le taux standardisé sur la population mondiale (TSM) de l’incidence est passé de 4,6 en 1987 à 9 en 2016 pour 100 000, la mortalité de 0,6 à 0,2 pour 100 000 pour la même période. Le pic d’incidence se situe entre 30 et 35 ans.ConclusionEn 30 ans, l’incidence des tumeurs testiculaire à fortement augmenter dans l’Hérault, on observe une faible diminution de sa mortalité sur cette même période. Ces données analytiques seront améliorées par le développement du Registre de l’Hérault Spécialisé en onco-urologie (RHESOU).
Published: 2020

26. Le cancer du rein dans le département de l’Hérault : résultats de 30 ans d’enregistrement (1987–2016)

Author: O. Delbos, N. Korahanis, X. Rebillard, Rodolphe Thuret, J. Bringer, D. Ayuso, M. Hutin, D. Rizet, T. Brigitte, G. Poinas, François Iborra, Clinique Beau Soleil [Montpellier], Registre des Tumeurs de l'Hérault, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Aide à la Décision pour une Médecine Personnalisé - Laboratoire de Biostatistique, Epidémiologie et Recherche Clinique - EA 2415 (AIDMP), Université Montpellier 1 (UM1)-Université de Montpellier (UM), Université de Montpellier (UM), CRP Clinique du Parc, Castelnau-Le-Lez, Clinique Saint-Jean - Sud de France [Montpellier], Clinique du Millénaire - Oc Santé [Montpellier], Oc Santé [Montpellier], Polyclinique Saint Privat, and Hôpitaux du Bassin de Thau (Sète)
Subjects: 03 medical and health sciences, 0302 clinical medicine, business.industry, 030220 oncology & carcinogenesis, Urology, 030232 urology & nephrology, Medicine, business, [SDV.MHEP.UN]Life Sciences [q-bio]/Human health and pathology/Urology and Nephrology, Humanities, 3. Good health
Abstract: International audience; ObjectifsL’objectif de cette étude est de présenter l’évolution de l’épidémiologie du cancer du rein dans l’Hérault à partir des données collectées par le registre des tumeurs de l’Hérault (RTH) sur une période de 30 ans.MéthodesÀ partir de la base de données du RTH, nous avons étudié l’évolution du cancer du rein de 1987 à 2016. Nous avons analysé les données concernant l’incidence, la mortalité, l’anatomopathologie des tumeurs et leur stade au diagnostic. Nous avons comparé ces résultats aux données nationales et internationales.RésultatsNous avons recensé 3766 nouveaux cas de cancers du rein : 2626 chez l’homme (69,7 %) et 1140 chez la femme (30,3 %). En 2016, le cancer du rein était le 8e cancer tous sexes confondus, le 7e cancer chez l’homme et le 11e chez la femme. Entre 1987 et 2016, le nombre de nouveaux cas de cancer du rein a été multiplié par 4,2 chez l’homme et par 3,3 chez la femme. Le nombre de formes localisées a augmenté de 9 % en 30 ans. En 2016, la probabilité d’être atteint d’un cancer du rein avant 75 ans est de 2,11 % pour un homme et de 0,62 % pour une femme (Fig. 1).ConclusionEn 30 ans, l’incidence du cancer du rein a fortement augmenté dans l’Hérault alors que l’on observe une diminution de sa mortalité. Ces données analytiques seront améliorées par le développement du Registre de l’Hérault Spécialisé en Onco-Urologie (RHESOU).
Published: 2020

27. Efficacy and tolerance of botulinum toxin injections after sacral nerve stimulation failure for idiopathic overactive bladder

Author: Sandy Lacombe, Maximilien Baron, Loïc Le Normand, Fanny Paret, Marie-Aimée Perrouin-Verbe, Jean-Nicolas Cornu, Service d'urologie [Rouen], Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-CHU Rouen, Normandie Université (NU), Centre hospitalier universitaire de Nantes (CHU Nantes), Clinique Beau Soleil [Montpellier], Nutrition, inflammation et dysfonctionnement de l'axe intestin-cerveau (ADEN), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institute for Research and Innovation in Biomedicine (IRIB), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), UNIROUEN - UFR Santé (UNIROUEN UFR Santé), and Normandie Université (NU)-Normandie Université (NU)
Subjects: Male, medicine.medical_specialty, Urge urinary incontinence, Urology, Lumbosacral Plexus, 030232 urology & nephrology, Acetylcholine Release Inhibitors, Urinary incontinence, Electric Stimulation Therapy, 03 medical and health sciences, 0302 clinical medicine, Primary outcome, medicine, [SDV.MHEP.PHY]Life Sciences [q-bio]/Human health and pathology/Tissues and Organs [q-bio.TO], Humans, Treatment Failure, Botulinum Toxins, Type A, ComputingMilieux_MISCELLANEOUS, Aged, Retrospective Studies, 030219 obstetrics & reproductive medicine, Urinary bladder, business.industry, Urinary Bladder, Overactive, Middle Aged, medicine.disease, Botulinum toxin, 3. Good health, Discontinuation, medicine.anatomical_structure, Administration, Intravesical, Treatment Outcome, Urinary Incontinence, Sacral nerve stimulation, Overactive bladder, Female, Neurology (clinical), medicine.symptom, business, medicine.drug
Abstract: Introduction Management of idiopathic overactive bladder (iOAB) after the failure of sacral nerve modulation (SNM) is very challenging. To the best of our knowledge, no study has evaluated the use of botulinum toxin A (BoNT-A) after SNM failure for iOAB. The aim of this study is to evaluate the tolerance and efficacy of BoNT-A injection after the failure of SNM for iOAB. Methods We conducted a retrospective multicentric analysis of all patients who had received either onabotulinumtoxinA or abobotulinumtoxinA intradetrusor injection for iOAB after SNM failure, between January 2004 and December 2017. The primary outcome was the percentage of success of first BoNT-A injection (either resolution of their urinary incontinence or their frequency or more than 50% reduction in frequency). Secondary outcomes were results of urodynamic studies, complications, total number of injections, causes of withdrawal, and subsequent treatment. Results Seventy-six patients (62 female) were included. The percentage of success of first BoNT-A injection was 43.4% (n = 33). All overactive bladder symptoms were significantly improved on the 3-day bladder diary. Twenty-eight patients (36.8%) were put under clean intermittent self-catheterization transitory. After a mean follow-up of 57.7 (±38.5) months, median number of injections was 2 (1-15). Overall, 42 patients (55.2%) stopped injections during follow-up. The estimated 36-months discontinuation-free rate was 48.1%. Mean cause of discontinuation was a primary failure (n = 32; 42.1%). Conclusion BoNT-A can be used in SNM nonresponders with a success rate of 43.4% but is associated with a high long-term discontinuation rate.
Published: 2019

28. Clinical evaluation of the Uphold LITE mesh for the surgical treatment of anterior and apical prolapse: A prospective, multicentre trial

Author: Lucie Allegre, M. Cayrac, Christophe Courtieu, Renaud de Tayrac, Pascale Fabbro Peray, Christophe Demattei, Brigitte Fatton, Philippe Debodinance, Xavier Fritel, Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), Centre Hospitalier de Dunkerque, BESPIM, Aide à la Décision pour une Médecine Personnalisé - Laboratoire de Biostatistique, Epidémiologie et Recherche Clinique - EA 2415 (AIDMP), Université Montpellier 1 (UM1)-Université de Montpellier (UM), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Service de gynécologie et obstétrique [Poitiers], Centre hospitalier universitaire de Poitiers (CHU Poitiers), and Clinique Beau Soleil [Montpellier]
Subjects: Reoperation, medicine.medical_specialty, complications, Urology, 030232 urology & nephrology, Uphold LITE, [SDV.MHEP.UN]Life Sciences [q-bio]/Human health and pathology/Urology and Nephrology, Pelvic Organ Prolapse, 03 medical and health sciences, 0302 clinical medicine, Quality of life, Recurrence, Risk Factors, Clinical endpoint, Medicine, Humans, Prospective Studies, Risk factor, Stage (cooking), Adverse effect, Aged, 030219 obstetrics & reproductive medicine, business.industry, composite outcome, Middle Aged, Surgical Mesh, transvaginal mesh, 3. Good health, Surgery, Treatment Outcome, Apical prolapse, Quality of Life, Urologic Surgical Procedures, Female, Neurology (clinical), Patient Safety, Sexual function, business, Complication, Follow-Up Studies
Abstract: International audience; Aims: To evaluate the safety and efficacy of the Uphold LITE mesh in the treatment of pelvic organ prolapse at 12-month follow-up.Methods: Women undergoing a mesh surgery due to an anterior prolapse plus a symptomatic anterior prolapse (classed as pelvic organ prolapse quantification stage ≥2) were included in this prospective, multicentre, observational study. The primary endpoint was a composite outcome including a good anatomical correction, no prolapse symptoms, and no reintervention for an anterior or apical recurrent prolapse within 12 months of surgery. Secondary outcomes included safety, improvements in quality of life (QoL), and risk factor for recurrence. This study was registered with ClinicalTrials.gov, number NCT01559168.Results: A total of 121 patients were included. Symptomatic and anatomic cure rates were 94% (95 of 101) and 76.8% (76 of 99), respectively. The composite success rate was 72.4% (71 of 98). The rate of reoperation for apical or anterior recurrent prolapse was 3.9% (4 of 103). Anatomical anterior or apical recurrence occurred in 18.2% (18 of 97) and 7.2% (7 of 97) of patients, respectively. The composite success rate was significantly higher in centres where more than 30 patients had been treated (80% vs 50%; P = .045). The rate of serious complication was 5.4% (6 of 111). Improvements were recorded in QoL including sexual function.Conclusions: The Uphold LITE mesh procedure provides satisfactory outcomes in the treatment of anterior and apical prolapse, particularly in high-volume centres. The rates of adverse effects and reintervention for recurrent prolapse were acceptable.
Published: 2019

29. Ultrasons focalisés de haute intensité vs prostatectomie totale dans le traitement à visée curative du cancer localisé de la prostate ISUP 1 et 2 : EIG et résultats fonctionnels à 12 mois

Author: Albert Gelet, Pascal Rischmann, Nadine Houede, A. Villers, T. Chevallier, X. Rebillard, B. Occéan, P. Coloby, Service d'urologie [CH René Dubos Pontoise], Centre Hospitalier René Dubos [Pontoise], Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL), Clinique Beau Soleil [Montpellier], CHU Lille, Hôpital de Rangueil, and CHU Toulouse [Toulouse]
Subjects: Gynecology, 03 medical and health sciences, medicine.medical_specialty, 0302 clinical medicine, business.industry, 030220 oncology & carcinogenesis, Urology, 030232 urology & nephrology, Medicine, [SDV.CAN]Life Sciences [q-bio]/Cancer, business, 3. Good health
Abstract: International audience; Objectifs : étude prospective multicentrique ouverte comparant l’efficacité carcinologique et les conséquences fonctionnelles d’un traitement conservateur par ultrasons focalisés de haute intensité (HIFU) à la prostatectomie totale (PT) pour adénocarcinome prostatique localisé de stades ISUP 1 (non éligibles à la surveillance active) et ISUP 2. Nous rapportons ici les EIG et résultats fonctionnels à 12 mois.Méthodes : de février 2015 à septembre 2019, 3364 patients (HIFU : 1988, PT : 1376) ont été inclus de façon prospective dans 42 centres. Âge médian : 74,6 vs 65 ; PSA médian : 7,11 vs 6,97 (p = 0,4). Les EIG ont été transmis à l’Agence nationale selon les standards internationaux.Objectifs fonctionnels de l’étude : IPSS, continence (USP), fonction érectile (IIEF5), qualité de vie (EORTC QLQ-C30) à 12 mois.Résultats : les durées médianes d’hospitalisation initiale ont été respectivement de 1 et 4 jours. Cinquante-trois EIG Clavien–Dindo ≥ IIIa : 32 HIFU (1,6 %) et 21 PT (1,5 %). Aucun risque préalablement inconnu n’a été mis en évidence. Onze cas de fistules ont été rapportés : bras HIFU : 3/1988 (1,5/1000) fistules (2 uro-digestives, 1 urinaire) ; bras PT : 8/1376 (5,8/1000) fistules (7 urinaires, 1 digestive). Tous les cas ont été guéris. Vingt-trois décès ont été enregistrés et sont non imputables. Résultats fonctionnels (HIFU vs PT) : IPSS médian : 4 vs 3, IPSS QdV médian : 1 vs 1 ; continence score médian : 0 vs 1 (p < 0,005) ; IIEF5 (Δ médianes pré- et postopératoires) 1 vs −9 (p < 0,0001) ; EORTC QLQ-C30 : 90,7 vs 93,4.Conclusion : une proportion supérieure de réhospitalisations a été constatée après HIFU. Plusieurs explications sont suggérées : l’âge plus élevé des patients, la durée d’hospitalisation initiale très brève et la gestion non standardisée des accidents rétentionnels. En dehors de l’IPSS, les conséquences fonctionnelles (incontinence, dysfonction érectile) sont significativement moins importantes pour l’HIFU que pour la prostatectomie à 12 mois postopératoires. La qualité de vie post-thérapeutique des deux groupes reste élevée, et malgré une différence d’âge de près de dix ans, est comparable.
Published: 2020

30. Le cancer de la prostate dans le département de l’Hérault : résultats de 30 ans d’enregistrement (1987–2016)

Author: François Iborra, Rodolphe Thuret, D. Azria, O. Delbos, G. Poinas, X. Rebillard, D. Rizet, S. Abdel-Hamid, J. Bringer, O. Riou, G. Aujoulat, Brigitte Trétarre, D. Ayuso, Clinique Beau Soleil [Montpellier], Registre des Tumeurs de l'Hérault, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Aide à la Décision pour une Médecine Personnalisé - Laboratoire de Biostatistique, Epidémiologie et Recherche Clinique - EA 2415 (AIDMP), Université Montpellier 1 (UM1)-Université de Montpellier (UM), Université de Montpellier (UM), CRP Clinique du Parc, Castelnau-Le-Lez, Clinique Saint-Jean - Sud de France [Montpellier], Clinique du Millénaire - Oc Santé [Montpellier], Oc Santé [Montpellier], Hôpitaux du Bassin de Thau (Sète), Polyclinique Saint Privat, Institut du Cancer de Montpellier (ICM), Institut de Recherche en Cancérologie de Montpellier (IRCM - U1194 Inserm - UM), and CRLCC Val d'Aurelle - Paul Lamarque-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)
Subjects: Gynecology, 03 medical and health sciences, medicine.medical_specialty, 0302 clinical medicine, business.industry, 030220 oncology & carcinogenesis, Urology, 030232 urology & nephrology, Medicine, business, [SDV.MHEP.UN]Life Sciences [q-bio]/Human health and pathology/Urology and Nephrology, 3. Good health
Abstract: International audience; ObjectifsL’objectif de cette étude est de présenter l’évolution de l’épidémiologie du cancer de la prostate dans l’Hérault à partir des données collectées par le registre des tumeurs de l’Hérault (RTH) sur une période de 30 ans.MéthodesÀ partir de la base de données du RTH, nous avons étudié l’évolution du cancer de la prostate de 1987 à 2016. Nous avons analysé les données concernant l’incidence, la mortalité, l’anatomopathologie des tumeurs et leur stade au diagnostic. Nous avons comparé ces résultats aux données nationales et internationales.RésultatsNous avons recensé 21 261 nouveaux cas de cancers de la prostate. Entre 1987 et 2016 le nombre de nouveaux cas de cancer de prostate a été multiplié par 2,8 avec un pic d’incidence en 2003. Le taux standardisé sur la population mondiale (TSM) de l’incidence est passé de 32,4 à 90,3 pour 100 000, la mortalité de 13,2 à 11,5 pour 100 000. Entre 2007 et 2015, le nombre cancer diagnostiqué au stade métastatique est passé de 5,1 % à 8,5 %, de même le taux de pT3 est passé de 17 % à 27,4 %. En 2016, la probabilité d’être atteint d’un cancer de prostate avant 75 ans est de 12,28 % (Fig. 1).ConclusionEn 30 ans, l’incidence du cancer de la prostate a fortement augmenté dans l’Hérault alors que l’on observe une diminution de sa mortalité. Ces données analytiques seront améliorées par le développement du Registre de l’Hérault Spécialisé en Onco-Urologie (RHESOU).
Published: 2020

31. SMPD1 variants do not have a major role in rapid eye movement sleep behavior disorder

Author: Marco Toffoli, Uladzislau Rudakou, Anna Heidbreder, Michele T.M. Hu, Isabelle Arnulf, Lynne Krohn, Jean-François Gagnon, Femke Dijkstra, Yves Dauvilliers, Beatriz Abril, Elena Antelmi, Brit Mollenhauer, Annette Janzen, Naomi C. Futhey, Ambra Stefani, Jacques Montplaisir, W. H. Oertel, David Kemlink, Evi Holzknecht, Armaghan Alam, Paul Cannon, Luigi Ferini-Strambi, Guy A. Rouleau, Claudia Trenkwalder, Mineke Viaene, Karel Sonka, Birgit Högl, Christelle Charley Monaca, Ronald B. Postuma, Monica Puligheddu, Alex Desautels, Mariarosaria Valente, Bradley F. Boeve, Karl Heilbron, Valérie Cochen De Cock, Michela Figorilli, Friederike Sixel-Döring, Ziv Gan-Or, Gian Luigi Gigli, Jennifer A. Ruskey, Giuseppe Plazzi, Rudakou, U., Futhey, N. C., Krohn, L., Ruskey, J. A., Heilbron, K., Cannon, P., Alam, A., Arnulf, I., M. T. M., Hu, Montplaisir, J. Y., Gagnon, J. -F., Desautels, A., Dauvilliers, Y., Toffoli, M., Gigli, G. L., Valente, M., Hogl, B., Stefani, A., Holzknecht, E., Sonka, K., Kemlink, D., Oertel, W., Janzen, A., Plazzi, G., Antelmi, E., Figorilli, M., Puligheddu, M., Mollenhauer, B., Trenkwalder, C., Sixel-Doring, F., De Cock, V. C., Monaca, C. C., Heidbreder, A., Ferini-Strambi, L., Dijkstra, F., Viaene, M., Abril, B., Boeve, B. F., Postuma, R. B., Rouleau, G. A., Gan-Or, Z., Salvy-Córdoba, Nathalie, Montreal Neurological Institute and Hospital, McGill University = Université McGill [Montréal, Canada], 23andMe Inc., Institut du Cerveau = Paris Brain Institute (ICM), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Nuffield Department of Clinical Neurosciences [Oxford], University of Oxford, Centre Hospitalier de l'Université de Montréal (CHUM), Université de Montréal (UdeM), Centre d'études avancées en Médecine du Sommeil (CEAMS), Université de Montréal (UdeM)-Hôpital du Sacré-Coeur de Montréal, Université du Québec à Montréal = University of Québec in Montréal (UQAM), Hôpital Gui de Chauliac [Montpellier], Neuropsychiatrie : recherche épidémiologique et clinique (PSNREC), Université Montpellier 1 (UM1)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Università degli Studi di Udine - University of Udine [Italie], UCL Institute of Neurology, National Hospital for Neurology and Neurosurgery, Queen Square, London, University of Udine and University Hospital of Udine, Innsbruck Medical University = Medizinische Universität Innsbruck (IMU), First Faculty of Medicine Charles University [Prague], Philipps Universität Marburg = Philipps University of Marburg, Alma Mater Studiorum Università di Bologna [Bologna] (UNIBO), Institute of Neurological Sciences of Bologna IRCCS, University of Cagliari, Paracelsus-Elena-Klinik, Kassel, Germany., department of neurology, clinical dementia center and DZNE, goettingen, Allemagne., Georg-August-University = Georg-August-Universität Göttingen, Department of Psychiatry and Psychotherapy, University Medical Center Goettingen (UMG), Göttingen, Clinique Beau Soleil [Montpellier], Euromov (EuroMov), Université de Montpellier (UM), CHU Lille, University Hospital Münster - Universitaetsklinikum Muenster [Germany] (UKM), Universita Vita Salute San Raffaele = Vita-Salute San Raffaele University [Milan, Italie] (UniSR), Algemeen Ziekenhuis Sint-Dimpna, Hôpital Universitaire Carémeau [Nîmes] (CHU Nîmes), Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), Mayo Clinic [Rochester], Hôpital du Sacré-Coeur de Montréal, and Department of Human Genetics [Montréal]
Subjects: Male, 0301 basic medicine, Aging, REM sleep behavior disorder, Disease, Bioinformatics, European descent, Behavior disorder, 0302 clinical medicine, Medicine, MESH: Genetic Variation, MESH: High-Throughput Nucleotide Sequencing, MESH: Genetic Association Studies, education.field_of_study, General Neuroscience, sphingomyelin phosphodiesterase 1, High-Throughput Nucleotide Sequencing, MESH: Negative Results, MESH: Sleep Wake Disorders, Association study, Sphingomyelin Phosphodiesterase, Female, Sphingomyelin phosphodiesterase 1, Sleep Wake Disorders, Rapid eye movement sleep, Sleep, REM, [SDV.GEN.GH] Life Sciences [q-bio]/Genetics/Human genetics, association study, 03 medical and health sciences, Humans, education, Genetic Association Studies, MESH: Humans, business.industry, Dementia with Lewy bodies, [SCCO.NEUR]Cognitive science/Neuroscience, [SCCO.NEUR] Cognitive science/Neuroscience, Genetic Variation, medicine.disease, MESH: Sleep, REM, MESH: Male, 030104 developmental biology, [SDV.GEN.GH]Life Sciences [q-bio]/Genetics/Human genetics, MESH: Sphingomyelin Phosphodiesterase, Neurology (clinical), Geriatrics and Gerontology, business, MESH: Female, Negative Results, 030217 neurology & neurosurgery, Developmental Biology
Abstract: International audience; Mutations in the sphingomyelin phosphodiesterase 1 (SMPD1) gene were reported to be associated with Parkinson's disease and dementia with Lewy bodies. In the current study, we aimed to evaluate the role of SMPD1 variants in isolated rapid eye movement sleep behavior disorder (iRBD). SMPD1 and its untranslated regions were sequenced using targeted next-generation sequencing in 959 iRBD patients and 1287 controls from European descent. Our study reports no statistically significant association of SMPD1 variants and iRBD. It is hence unlikely that SMPD1 plays a major role in iRBD.
Published: 2020

32. Long-term follow-up of patients treated by transvaginal mesh repair for anterior prolapse

Author: L. Panel, Martha Duraes, C. Courtieu, Arnaud Cornille, Clinique Beau Soleil [Montpellier], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), and Université de Montpellier (UM)
Subjects: Reoperation, medicine.medical_specialty, Long term follow up, 030232 urology & nephrology, Polypropylene mesh, [SDV.MHEP.GEO]Life Sciences [q-bio]/Human health and pathology/Gynecology and obstetrics, Asymptomatic, 03 medical and health sciences, 0302 clinical medicine, Patient satisfaction, Quality of life, Vaginal surgery, Recurrence, Surveys and Questionnaires, medicine, Humans, Postoperative Period, Prospective Studies, Stage (cooking), Prospective cohort study, Aged, 030219 obstetrics & reproductive medicine, Pelvic floor, business.industry, Obstetrics and Gynecology, [SDV.BDLR]Life Sciences [q-bio]/Reproductive Biology, Middle Aged, Surgical Mesh, Surgery, Pelvic organ prolapse, Distress, Treatment Outcome, medicine.anatomical_structure, Reproductive Medicine, Patient Satisfaction, Vagina, Quality of Life, Female, medicine.symptom, business, Follow-Up Studies, Long term results
Abstract: Objective The aim of the study was to assess 5 years outcome of transvaginal single incision mesh surgery (SIMS) for anterior pelvic organ prolapse (POP). Study design This was a prospective study including all patients from January 2009 to December 2012 who underwent SIMS for symptomatic anterior prolapse stage ≥2, according to POP Quantification (POP-Q). Symptoms and quality of life were assessed using validated questionnaires: Pelvic Floor Distress Inventory (PFDI-20), Pelvic Floor Impact questionnaire (PFIQ-7), and Prolapse/ Incontinence Sexual Questionnaire (PISQ-12). Main outcome was subjective success (question 3 of PFDI-20 score = 0). Mesh-related complications, objective and functional outcomes were used as the secondary outcomes. Results 270 patients were included in the study. Median follow-up was 5,7 years [4,5–8,2]. Subjective success rate was 86,6% at 5 years. Objective success rate was 53,1% at 5 years. At 5 years, composite failure (subjective + objective) occurred for 17 patients (12%), 7 patients with direct recurrence and 10 with indirect recurrence. Re-treatment was performed in six patients (2,8%; 3 hysterectomies for apical recurrence and 3 posterior repairs for posterior recurrence). One case (0,4%) of asymptomatic mesh exposure occurred. The reoperation rate for mesh-related complications was 3,4%. At 5 years, de novo dyspareunia rate was 11,7%, 3,9% considered as mesh-related. A significant improvement was noted for symptoms and quality of life. Conclusion Five-year results demonstrate that vaginal mesh surgery provides a durable and safe repair of anterior compartment prolapse with a low rate of mesh-related complications and reoperations. Between the 2- and 5-year follow-up, patient satisfaction and associated improvements in prolapse-specific symptoms were sustained and minimal new morbidity occurred.
Published: 2018

33. Rhythmic abilities and musical training in Parkinson’s disease: do they help?

Author: Valentin Bégel, Valérie Driss, Dobromir Dotov, V. Cochen De Cock, Christian Geny, S. Dalla Bella, Benoît G. Bardy, Petra Ihalainen, C. Lebrun, N. Landragin, Florence Galtier, Marie Christine Picot, Euromov (EuroMov), Université de Montpellier (UM), CIC Montpellier, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-CHU Saint-Eloi-Institut National de la Santé et de la Recherche Médicale (INSERM), Clinique Beau Soleil [Montpellier], Clinique du Millénaire - Oc Santé [Montpellier], Oc Santé [Montpellier], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Université du Québec à Montréal = University of Québec in Montréal (UQAM), Service de neurologie [Saint-Antoine], Université Pierre et Marie Curie - Paris 6 (UPMC)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), Centre de pharmacologie et innovation dans le diabète (CPID), Centre National de la Recherche Scientifique (CNRS)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Université Montpellier 1 (UM1), Hôpital Pasteur [Nice] (CHU), Domaines Océaniques (LDO), Institut national des sciences de l'Univers (INSU - CNRS)-Université de Brest (UBO)-Observatoire des Sciences de l'Univers-Institut d'écologie et environnement-Centre National de la Recherche Scientifique (CNRS), Sanofi Pasteur [Marcy-l'Étoile, France], Biocommunication en Cardio-Métabolique (BC2M), Centre de résonance magnétique biologique et médicale (CRMBM), Assistance Publique - Hôpitaux de Marseille (APHM)-Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS), Institut Charles Sadron (ICS), Université de Strasbourg (UNISTRA)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Réseau nanophotonique et optique, Centre National de la Recherche Scientifique (CNRS)-Université de Strasbourg (UNISTRA)-Université de Haute-Alsace (UHA) Mulhouse - Colmar (Université de Haute-Alsace (UHA))-Centre National de la Recherche Scientifique (CNRS)-Université de Strasbourg (UNISTRA)-Université de Haute-Alsace (UHA) Mulhouse - Colmar (Université de Haute-Alsace (UHA))-Matériaux et nanosciences d'Alsace (FMNGE), Institut de Chimie du CNRS (INC)-Université de Strasbourg (UNISTRA)-Université de Haute-Alsace (UHA) Mulhouse - Colmar (Université de Haute-Alsace (UHA))-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université de Strasbourg (UNISTRA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), LEBRUN, Cindy, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Hôpital Saint Eloi (CHRU Montpellier), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM), International Laboratory for Brain, Music and Sound Research (BRAMS), Université de Montréal (UdeM), and University of Finance and Management in Warsaw (WSFiZ)
Subjects: medicine.medical_specialty, Parkinson's disease, media_common.quotation_subject, Audiology, behavioral disciplines and activities, Article, lcsh:RC346-429, 050105 experimental psychology, [SCCO]Cognitive science, 03 medical and health sciences, Cellular and Molecular Neuroscience, 0302 clinical medicine, Rhythm, Perception, medicine, 0501 psychology and cognitive sciences, ComputingMilieux_MISCELLANEOUS, lcsh:Neurology. Diseases of the nervous system, media_common, [SDV.MHEP] Life Sciences [q-bio]/Human health and pathology, 05 social sciences, Cognitive flexibility, [SDV.NEU.SC]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Cognitive Sciences, Cognition, medicine.disease, Gait, humanities, Musicality, Neurology, Neurology (clinical), Singing, Psychology, human activities, [SDV.NEU.SC] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Cognitive Sciences, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology, 030217 neurology & neurosurgery
Abstract: Rhythmic auditory cues can immediately improve gait in Parkinson’s disease. However, this effect varies considerably across patients. The factors associated with this individual variability are not known to date. Patients’ rhythmic abilities and musicality (e.g., perceptual and singing abilities, emotional response to music, and musical training) may foster a positive response to rhythmic cues. To examine this hypothesis, we measured gait at baseline and with rhythmic cues in 39 non-demented patients with Parkinson’s disease and 39 matched healthy controls. Cognition, rhythmic abilities and general musicality were assessed. A response to cueing was qualified as positive when the stimulation led to a clinically meaningful increase in gait speed. We observed that patients with positive response to cueing (n = 17) were more musically trained, aligned more often their steps to the rhythmic cues while walking, and showed better music perception as well as poorer cognitive flexibility than patients with non-positive response (n = 22). Gait performance with rhythmic cues worsened in six patients. We concluded that rhythmic and musical skills, which can be modulated by musical training, may increase beneficial effects of rhythmic auditory cueing in Parkinson’s disease. Screening patients in terms of musical/rhythmic abilities and musical training may allow teasing apart patients who are likely to benefit from cueing from those who may worsen their performance due to the stimulation., Musicality in Parkinson’s disease: Trained to follow the beat Listening to rhythmic auditory cues improves the ability to walk in patients with Parkinson’s disease (PD). Previous studies have shown that music can help patients with neurological disorders synchronize their movements to a beat. An international study led by Valérie Cochen De Cock at Clinique Beau Soleil in Montpellier (France) and Simone Dalla Bella at the International Laboratory For Brain, Music and Sound Research (BRAMS) in Montreal (Canada), measured gait speed in 39 patients with PD without dementia in response to rhythmic stimulation. Twenty-two patients increased their gait speed by spontaneously synchronizing their steps to the beat. The remaining 17 patients showed no effect or significant worsening of gait performance (e.g., smaller step length). The patients who benefited the most from rhythmic cues exhibited better rhythmic skills and were more musical than the others. Assessing musical abilities may serve to identify patients who are likely to benefit from this music-based intervention and may foster individualization of the treatment.
Published: 2018

34. Abdominal obesity and prostate cancer risk: epidemiological evidence from the EPICAP study

Author: Sylvie Cénée, C Lavalette, Florence Menegaux, Pierre-Jean Lamy, Brigitte Trétarre, Xavier Rebillard, ONOFRE, Mélanie, Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, Institut du Cancer de Montpellier (ICM), and Clinique Beau Soleil [Montpellier]
Subjects: 0301 basic medicine, medicine.medical_specialty, obesity, Waist, Epidemiology, Population, 030209 endocrinology & metabolism, body mass index, [SDV.CAN]Life Sciences [q-bio]/Cancer, Overweight, Logistic regression, [SDV.MHEP.UN]Life Sciences [q-bio]/Human health and pathology/Urology and Nephrology, 03 medical and health sciences, Waist–hip ratio, 0302 clinical medicine, [SDV.CAN] Life Sciences [q-bio]/Cancer, Internal medicine, medicine, education, Abdominal obesity, 2. Zero hunger, [SDV.MHEP.EM] Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolism, education.field_of_study, business.industry, Public Health, Environmental and Occupational Health, Odds ratio, Anthropometry, [SDV.MHEP.EM]Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolism, medicine.disease, prostate cancer, waist circumference, Obesity, [SDV.MHEP.UN] Life Sciences [q-bio]/Human health and pathology/Urology and Nephrology, 3. Good health, 030104 developmental biology, Oncology, [SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie, 030220 oncology & carcinogenesis, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, waist-hip ratio, medicine.symptom, business, Body mass index, Research Paper, Demography
Abstract: Introduction Obesity is associated with an increased risk of several cancers, such as breast or colorectal cancers. However, the relationship between obesity and prostate cancer (PCa) remains controversial. Indeed, inconsistent results have been reported between body mass index (BMI) and PCa risk, while some associations have been reported with other anthropometric indicators, such as waist circumference (WC) or waist-hip ratio (WHR), which would better illustrate the concept of body fat distribution. Therefore, we assessed a possible association between anthropometric indicators and PCa risk based on data from the EPICAP study. Methods EPICAP in a French population-based case-control study that enrolled 819 incident cases of PCa diagnosed in 2012 and 2013, aged less than 75 years old and residing in the department of Herault, France. Controls were 879 age-matched (± 5 y) individuals living in the same geographic area. Face-to-face interviews, using a standardized computerized questionnaire, gathered information about sociodemographic characteristics, personal medical history, lifestyle factors, physical activity, residential and occupational history. Anthropometric indicators have also been collected through the questionnaire (self-report of height at 18 years old and weight every decades) or anthropometric measures at time of interview (height, weight, waist and hip circumferences). Logistic regression models were used to assess odds ratios (ORs) for the associations between anthropometric indicators (BMI, WC and WHR) and PCa risk. Analyses were systematically adjusted for age (5-year period), family history of prostate cancer in first-degree relatives and race (Caucasians, others). Analyses were also adjusted for other potential confounding factors such as educational level or physical activity. Separate analyses were conducted by prostate cancer aggressiveness according to the Gleason score (low or intermediate score ≤ 7 [including 3 + 4], high score ≥ 7 [including 4 + 3]). Seeking for relevant interaction between BMI and WC or WHR, we performed stratified analyses according to BMI overweight cut-point (25 kg/m2) defined by the World Health Organization. Results Overall, 47.8% of men were overweight and 23.4% were obese, similarly distributed between cases and controls (OR 0.98, 95% CI 0.78–1.23, OR 0.91 95% CI 0.67–1.23, respectively). We observed a slight, but not significant increased risk of PCa for men with a WC above 94 cm (OR 1.20, 95% CI 0.95–1.51) and an increased risk of PCa for men with a WHR greater or equal to 0.95 (OR 1.27, 95% CI 1.01–1.60), with more pronounced associations after adjustment for BMI (OR 1.48, 95% CI 1.11–1.97, OR 1.39, 95% CI 1.09–1.79, respectively). In addition, analyses stratified on BMI showed that men with a BMI 94 cm or WHR ≥ 0.95 (OR 1.63, 95% CI 1.05–2.52, OR 1.76, 95% CI 1.18–2.63, respectively). Nevertheless, interactions were not significant for WC (P = 0.23) and close to significance for WHR (P = 0.07). Associations regarding central obesity indicators, adjusted for BMI, were more pronounced in men with aggressive prostate cancer, either for WC > 94 cm (OR 2.30, 95% CI 1.38–3.83) or WHR ≥ 0.95 (OR 1.51, 95% CI 0.98–2.32). Conclusions Our results suggest that BMI itself is not associated with prostate cancer, while central obesity is associated with an increased risk of prostate cancer, especially aggressive prostate cancer.
Published: 2018

35. pH-operated hybrid silica nanoparticles with multiple H-bond stoppers for colon cancer therapy

Author: Marie Maynadier, G. Pop, Christophe Theron, U. Hibner, Marcel Garcia, E. Jacquet, Jeffrey I. Zink, Carole Carcel, Magali Gary-Bobo, S. Giret, O. Sgarbura, Audrey Gallud, P. Puche, D. Grégoire, M. Wong Chi Man, Virginie Bellet, Institut Charles Gerhardt Montpellier - Institut de Chimie Moléculaire et des Matériaux de Montpellier ( ICGM ICMMM ), Université Montpellier 1 ( UM1 ) -Université Montpellier 2 - Sciences et Techniques ( UM2 ) -Ecole Nationale Supérieure de Chimie de Montpellier ( ENSCM ) -Université de Montpellier ( UM ) -Centre National de la Recherche Scientifique ( CNRS ), Institut des Biomolécules Max Mousseron [Pôle Chimie Balard] ( IBMM ), Ecole Nationale Supérieure de Chimie de Montpellier ( ENSCM ) -Université de Montpellier ( UM ) -Centre National de la Recherche Scientifique ( CNRS ), NanoMedSyn, Institut de Génétique Moléculaire de Montpellier ( IGMM ), Université de Montpellier ( UM ) -Centre National de la Recherche Scientifique ( CNRS ), Clinique Beausoleil, Institut de recherche en cancérologie de Montpellier ( IRCM ), Université Montpellier 1 ( UM1 ) -CRLCC Val d'Aurelle - Paul Lamarque-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Université de Montpellier ( UM ), Department of Chemistry and Biochemistry, University of California Los Angeles, University of California at Los Angeles [Los Angeles] ( UCLA ), ANR, ANR-10-JCJC-1006,NanoMIS,Nanoparticules de silice hybride à empreinte moléculaire comme transporteur pH-sensible de prodrogues ( 2010 ), Clinique Beau Soleil [Montpellier], Department of Chemistry and Biochemistry ( UCLA ), Institut Charles Gerhardt Montpellier - Institut de Chimie Moléculaire et des Matériaux de Montpellier (ICGM), Ecole Nationale Supérieure de Chimie de Montpellier (ENSCM)-Institut de Chimie du CNRS (INC)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), Institut des Biomolécules Max Mousseron [Pôle Chimie Balard] (IBMM), NanoMedSyn (NMS), Institut de Génétique Moléculaire de Montpellier (IGMM), Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), Institut de Recherche en Cancérologie de Montpellier (IRCM - U1194 Inserm - UM), CRLCC Val d'Aurelle - Paul Lamarque-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Department of Chemistry and Biochemistry (UCLA), University of California [Los Angeles] (UCLA), University of California (UC)-University of California (UC), ANR-10-JCJC-1006,NanoMIS,Nanoparticules de silice hybride à empreinte moléculaire comme transporteur pH-sensible de prodrogues(2010), Wong Chi Man, Michel, Jeunes Chercheuses et Jeunes Chercheurs - Nanoparticules de silice hybride à empreinte moléculaire comme transporteur pH-sensible de prodrogues - - NanoMIS2010 - ANR-10-JCJC-1006 - JCJC - VALID, Institut Charles Gerhardt Montpellier - Institut de Chimie Moléculaire et des Matériaux de Montpellier (ICGM ICMMM), Ecole Nationale Supérieure de Chimie de Montpellier (ENSCM)-Centre National de la Recherche Scientifique (CNRS)-Université de Montpellier (UM)-Université Montpellier 1 (UM1)-Université Montpellier 2 - Sciences et Techniques (UM2)-Institut de Chimie du CNRS (INC), Centre National de la Recherche Scientifique (CNRS)-Institut de Chimie du CNRS (INC)-Université de Montpellier (UM)-Ecole Nationale Supérieure de Chimie de Montpellier (ENSCM), Centre National de la Recherche Scientifique (CNRS)-Université de Montpellier (UM), and University of California-University of California
Subjects: Colorectal cancer, General Chemical Engineering, Nanoparticle, Nanotechnology, 010402 general chemistry, [ CHIM ] Chemical Sciences, 01 natural sciences, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, [CHIM] Chemical Sciences, medicine, [CHIM]Chemical Sciences, [CHIM.MATE] Chemical Sciences/Material chemistry, Chemistry, [CHIM.MATE]Chemical Sciences/Material chemistry, General Chemistry, medicine.disease, Combinatorial chemistry, 3. Good health, 0104 chemical sciences, Bioavailability, Cell culture, [ CHIM.MATE ] Chemical Sciences/Material chemistry, 030220 oncology & carcinogenesis, Cancer cell, Nanocarriers, Cyanuric acid, Ex vivo
Abstract: International audience; The transport of anticancer molecules by nanoparticles has shown great promise in terms of bioavailability, concentrating drugs in the tumor area and minimizing drug side effects. Here, we report the high efficiency of pH-operated hybrid silica nanocarriers for colon cancer therapy. These silica nanoparticles carry the drugs which are tightly held by cyanuric acid as a new type of stopper. The latter can be autonomously removed upon acidic medium allowing a direct drug release inside the cancer cells. Importantly, the proof of concept was established by ex vivo experiments using primary cell cultures from patient biopsies.
Published: 2015

36. Prosbiotate: A Multicenter, Prospective Analysis of Infectious Complications after Prostate Biopsy

Author: Aliette Decock, Hubert Bugel, Bertrand Pogu, Pierre Mongiat-Artus, Patrick Coloby, Xavier Rebillard, Philippe Bertrand, S. Conquy, Franck Bruyère, Jean Dominique Doublet, Albert Sotto, Louis Bernard, Jean Paul Boiteux, S. Malavaud, G. Cariou, Service d'urologie [Tours], Hôpital Bretonneau-Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Université Francois Rabelais [Tours], Service d'épidémiologie [Toulouse], CHU Toulouse [Toulouse], Centre Hospitalier Régional Universitaire de Tours (CHRU TOURS), Service d'Urologie [CHU Saint-Louis], Université Paris Diderot - Paris 7 (UPD7)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Cancer et Transplantation : Physiopathologie et Réponse Thérapeutique (UMR 1165), Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier de Versailles André Mignot (CHV), Service d'urologie [CHU Cochin], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin [AP-HP], Université Paris Descartes - Paris 5 (UPD5), Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), Virulence bactérienne et maladies infectieuses (VBMI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), CHU Clermont-Ferrand, Hôpital de Châlons-en-Champagne, Clinique Beau Soleil [Montpellier], Service d'urologie [CH René Dubos Pontoise], Centre Hospitalier René Dubos [Pontoise], Centre Hospitalier Régional Universitaire de Tours (CHRU Tours)-Hôpital Bretonneau, Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Université Paris Diderot - Paris 7 (UPD7)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Centre Hospitalier de Versailles (CHV), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Cochin [AP-HP], Centre Hospitalier Régional Universitaire de Nîmes (CHRU Nîmes), and Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM)
Subjects: Male, medicine.medical_specialty, Prostate biopsy, Biopsy, Urology, Prostatitis, [SDV.MHEP.UN]Life Sciences [q-bio]/Human health and pathology/Urology and Nephrology, Risk Assessment, Sepsis, Prostate cancer, prostatitis, Prostate, medicine, Humans, Prospective Studies, Antibiotic prophylaxis, risk, Aged, medicine.diagnostic_test, business.industry, Incidence, Incidence (epidemiology), Middle Aged, medicine.disease, 3. Good health, Surgery, medicine.anatomical_structure, business
Abstract: International audience; PURPOSE:Prostate biopsy side effects have a role in the controversy over screening for prostate cancer. We measured the precise incidence of infection after prostate biopsy and determined risk factors.MATERIALS AND METHODS:We performed a prospective, multicenter study in France from April to June 2013. All prostate biopsies done during this period were included in study. A web based questionnaire was used to identify patient characteristics, biopsy methods and postoperative infectious episodes. External audit helped ensure data completeness. The primary outcome was the post-biopsy infection rate. We determined risk factors for infectious complications using univariate and multivariate analysis.RESULTS:The study included 2,718 patients, of whom 6% reported receiving antibiotics in the previous 6 months and 7.4% had a history of prostatitis. Recommended antibiotic prophylaxis consisting of 2 fluoroquinolone tablets 2 hours before examination for prostate biopsy was noted in 78.3% of cases. Post-biopsy sepsis was found in 76 subjects (2.8%). On multivariate analysis predictors of post-biopsy sepsis were noncompliance with antibiotic prophylaxis guidelines (OR 2.3, 95% CI 1.4-3.9, p = 0.001), antibiotic treatment in the previous 6 months (OR 2.1, 95% CI 1.1-3.9, p = 0.015) and a history of prostatitis (OR 1.7, 95% CI 1.2-2.4, p = 0.002).CONCLUSIONS:In this study the incidence of post-prostate biopsy sepsis was 2.8% and no deaths were reported. Risk factors identified on multivariate analysis were noncompliance with antibiotic prophylaxis according to guidelines, antibiotic treatment in the previous 6 months and a history of prostatitis.
Published: 2015

37. Prostatitis, other genitourinary infections and prostate cancer risk: Influence of non-steroidal anti-inflammatory drugs? Results from the EPICAP study

Author: Rodolphe Thuret, Brigitte Trétarre, O. Delbos, Sylvie Cénée, Miguelle Marous, Bruno Segui, Solène Doat, Paolo Soares, Xavier Rebillard, Pierre-Jean Lamy, Florence Menegaux, Centre de recherche en épidémiologie et santé des populations (CESP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris-Sud - Paris 11 (UP11)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Clinique Beau Soleil [Montpellier], Aide à la Décision pour une Médecine Personnalisé - Laboratoire de Biostatistique, Epidémiologie et Recherche Clinique - EA 2415 (AIDMP), Université Montpellier 1 (UM1)-Université de Montpellier (UM), CRLCC Val d'Aurelle - Paul Lamarque, Institut médical d'anayse génomique (IMAGENOME), Labosud, Polyclinique Saint Privat, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), and Université de Montpellier (UM)
Subjects: Adult, Male, Cancer Research, medicine.medical_specialty, genitourinary infections, Population, 030232 urology & nephrology, Prostatitis, [SDV.CAN]Life Sciences [q-bio]/Cancer, Logistic regression, Reproductive Tract Infections, 03 medical and health sciences, Prostate cancer, 0302 clinical medicine, Risk Factors, Internal medicine, Epidemiology, medicine, Humans, Urethritis, education, Aged, education.field_of_study, Genitourinary system, business.industry, Incidence, Anti-Inflammatory Agents, Non-Steroidal, Prostatic Neoplasms, Odds ratio, Middle Aged, medicine.disease, prostate cancer, Prognosis, 3. Good health, Oncology, inflammation, 030220 oncology & carcinogenesis, Case-Control Studies, Urinary Tract Infections, France, business, Follow-Up Studies
Abstract: International audience; Epidemiological studies have suggested that prostatitis may increase the risk of prostate cancer due to chronic inflammation. We studied the association between several genitourinary infections and the risk of prostate cancer based on data from the EPICAP study. EPICAP is a population-based case-control study conducted in the département of Hérault, France, between 2012 and 2014. A total of 819 incident cases and 879 controls have been face to face interviewed using a standardized questionnaire gathering information on known or suspected risk factors of prostate cancer, and personal history of genitourinary infections: prostatitis, urethritis, orchi-epididymitis, and acute pyelonephritis. Odds Ratios (OR) and their 95% confidence interval were estimated using multivariate unconditional logistic regression. Overall, 139 (18%) cases and 98 (12%) controls reported having at least one personal history of genitourinary infections (OR = 1.64 [1.23-2.20]). The risk increased with the number of infections (p-trend
Published: 2017

38. Prognostic impact of the inclusion of uPA/PAI-1 for adjuvant treatment decision-making in ER+/Her2− pN0 early breast cancers

Author: Aurélie Maran-Gonzalez, Marian Gutowski, Pierre-Emmanuel Colombo, Marie Alexandre, William Jacot, Simon Thezenas, Marie Viala, Séverine Guiu, Gilles Romieu, Pierre-Jean Lamy, Institut du Cancer de Montpellier (ICM), Clinique Beau Soleil [Montpellier], Institut de Recherche en Cancérologie de Montpellier (IRCM - U1194 Inserm - UM), and CRLCC Val d'Aurelle - Paul Lamarque-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)
Subjects: 0301 basic medicine, Oncology, Cancer Research, Receptor, ErbB-2, medicine.medical_treatment, [SDV]Life Sciences [q-bio], uPA/PAI-1, 0302 clinical medicine, Breast cancer, Recurrence, Antineoplastic Combined Chemotherapy Protocols, Aged, 80 and over, Middle Aged, Prognosis, 3. Good health, Treatment Outcome, Receptors, Estrogen, Chemotherapy, Adjuvant, 030220 oncology & carcinogenesis, Cohort, Biomarker (medicine), Female, Adjuvant, Adult, medicine.medical_specialty, Tailoring, Clinical Decision-Making, Breast Neoplasms, 03 medical and health sciences, Internal medicine, Plasminogen Activator Inhibitor 1, medicine, Biomarkers, Tumor, Humans, Pathological, Survival analysis, Aged, Neoplasm Staging, Gynecology, Chemotherapy, business.industry, Retrospective cohort study, medicine.disease, Survival Analysis, Urokinase-Type Plasminogen Activator, Adjuvant chemotherapy, 030104 developmental biology, Neoplasm Grading, business
Abstract: International audience; PURPOSE:Intermediate-risk early breast cancer (EBC) is a heterogeneous group in which adjuvant chemotherapy decision proves to be difficult. Clinical and pathological criteria are sometimes insufficient to determine the best therapeutic options, and validated biomarkers such as uPA/PAI-1, are needed to contribute to the decision-making. The objective of this study was to evaluate the clinical outcome of an unselected ER+/HER2- pN0 EBC cohort of patients in whom the routine clinical decision process included a prospective uPA/PAI-1 determination.METHOD:This monocentric retrospective study included 520 patients who underwent curative surgery in our institute between 2006 and 2011. Adjuvant therapeutic strategy was decided based on clinical-pathological data, altogether with a routine prospective determination of uPA/PAI-1 tumor levels using fresh, extemporaneously sampled tissue. We evaluated the correlation between uPA/PAI-1 levels, clinical-pathological variables, and the patient's outcome (relapse-free survival, RFS, and overall survival, OS).RESULT:Median follow-up was 5.4 years. The 5- and 10-year RFS rates were ,respectively, 95 and 89%, and the five-year OS rate was 96.3%. Forty percent of tumors had low uPA/PAI-1 levels. Seventy-five percent of patients with low uPA/PAI-1 levels did not receive chemotherapy, when 25% did. Sixty percent of patients with high uPA and/or PAI-1 levels received chemotherapy, while 40% did not. No statistical significant correlation was found between the uPA/PAI-1 levels and RFS or OS.CONCLUSION:The personalization of the patients' treatment using uPA/PAI-1 tumor levels allows the reversion of the well-known poor prognostic impact of high uPA/PAI-1 levels and strongly supports the use of this biomarker in clinical practice.
Published: 2017

39. External validation of the Donor Risk Index and the Eurotransplant Donor Risk Index on the French liver transplantation registry

Author: Audrey Winter, Etienne Audureau, Paul Landais, Christian Jacquelinet, Jean-Pierre Daurès, René Ecochard, Cyrille Feray, Françoise Roudot-Thoraval, Christophe Duvoux, Aide à la Décision pour une Médecine Personnalisé - Laboratoire de Biostatistique, Epidémiologie et Recherche Clinique - EA 2415 (AIDMP), Université Montpellier 1 (UM1)-Université de Montpellier (UM), Clinique Beau Soleil [Montpellier], Service d'hépato-gastro-entérologie [APHP Henri Mondor], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Service de santé publique [Mondor], Biostatistiques santé, Département biostatistiques et modélisation pour la santé et l'environnement [LBBE], Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 (LBBE), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 (LBBE), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS), Agence de la biomédecine [Saint-Denis la Plaine], BESPIM, Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), and Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-Hôpital Henri Mondor-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)
Subjects: Adult, Male, medicine.medical_specialty, Validation study, Adolescent, medicine.medical_treatment, Economic shortage, 030230 surgery, Liver transplantation, Risk Assessment, 03 medical and health sciences, Young Adult, 0302 clinical medicine, external validation, Risk index, medicine, Humans, Registries, Child, Aged, Hepatology, liver transplantation, business.industry, External validation, Infant, [SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, Middle Aged, Tissue Donors, prognostic score, Surgery, Transplantation, Organ procurement, Child, Preschool, Emergency medicine, 030211 gastroenterology & hepatology, Female, France, Risk assessment, business, donor risk
Abstract: International audience; BACKGROUND & AIMS:A major limitation to liver transplantation is organ shortage leading to the use of non-optimal liver grafts. The Donor Risk Index has been validated and recommended to select donors/organs. The Eurotransplant Donor Risk Index was derived from the Donor Risk Index. The objective of our study was to perform an external validation of both Donor Risk Index and Eurotransplant-Donor Risk Index against the French liver transplantation Cristal registry according to recommendations of the Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis.METHODS:Liver transplantations performed in France between 2009 and 2013 were used to perform the validation study for the Donor Risk Index and the Eurotransplant-Donor Risk Index respectively. We applied on the French data the models used to construct the Donor Risk Index and the Eurotransplant-Donor Risk Index respectively.RESULTS:Neither the Donor Risk Index nor the Eurotransplant-Donor Risk Index were validated against this dataset. Discrimination and calibration of these scores were not preserved according to our data. Important donor and candidates differences between our dataset and the Organ Procurement and Transplantation Network or the Eurotransplant datasets may explain why the Donor Risk Index and the Eurotransplant-Donor Risk Index appeared unadapted to the French transplant registry.CONCLUSION:Neither of these risk indexes were suitable to optimize the French liver allocation system. Thus, our next step will be to propose a general adaptive model for a Donor Risk Index.
Published: 2017

40. Radioactive iodine therapy, molecular imaging and serum biomarkers for differentiated thyroid cancer: 2017 guidelines of the French Societies of Nuclear Medicine, Endocrinology, Pathology, Biology, Endocrine Surgery and Head and Neck Surgery

Author: Abir Al Ghuzlan, Marie-Elisabeth Toubert, Sophie Leboulleux, Pierre-Jean Lamy, Slimane Zerdoud, Anne-Laure Giraudet, Isabelle Keller, Renaud Garrel, Elif Hindié, Lionel Groussin, Stéphane Bardet, Eric Mirallié, David Taïeb, Frederic Sebag, Laurence Leenhardt, Jérôme Clerc, Claire Bournaud, Médecine nucléaire, Département d'imagerie médicale [Gustave Roussy], Institut Gustave Roussy (IGR)-Institut Gustave Roussy (IGR), Service de médecine nucléaire [CHU Pitié-Salpétrière], CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Département de biologie et pathologie médicales [Gustave Roussy], Institut Gustave Roussy (IGR), Clinique Beau Soleil [Montpellier], Hôpital de la Timone [CHU - APHM] (TIMONE), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Institut Cochin (IC UM3 (UMR 8104 / U1016)), Centre National de la Recherche Scientifique (CNRS)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), [Institut Cochin] Département Endocrinologie, métabolisme, diabète (EMD) (EMD), Centre National de la Recherche Scientifique (CNRS)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital Haut-Lévêque [CHU Bordeaux], CHU Bordeaux [Bordeaux], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Pitié-Salpêtrière [APHP], Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), and Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)
Subjects: medicine.medical_specialty, Pathology, Consensus, Endocrinology, Diabetes and Metabolism, medicine.medical_treatment, [SDV]Life Sciences [q-bio], MEDLINE, 030209 endocrinology & metabolism, Biology, Iodine Radioisotopes, 03 medical and health sciences, 0302 clinical medicine, Endocrinology, Serum biomarkers, Internal medicine, Biomarkers, Tumor, medicine, Humans, Thyroid Neoplasms, Radionuclide Imaging, Thyroid cancer, ComputingMilieux_MISCELLANEOUS, business.industry, General Medicine, medicine.disease, Molecular Imaging, 3. Good health, Endocrine surgery, 030220 oncology & carcinogenesis, Thyroidectomy, Head and neck surgery, Neck Dissection, France, Radioactive iodine therapy, Nuclear Medicine, Molecular imaging, Nuclear medicine, business
Abstract: International audience
Published: 2017

41. Les conséquences sexuelles des traitements du cancer de la prostate : enquête auprès des membres de l’Association nationale des malades du cancer de la prostate

Author: Girier, D., Chevrot, A., Costa, P., Thuret, R., Faix, A., Mestre, A., Droupy, S., de l’Association française d’urologie, Comité d’andrologie et de médecine sexuelle, Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), Université de Montpellier (UM), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), and Clinique Beau Soleil [Montpellier]
Subjects: medicine.medical_specialty, Urology, 030232 urology & nephrology, Sexualité, [SDV.MHEP.UN]Life Sciences [q-bio]/Human health and pathology/Urology and Nephrology, Dysfonction érectile, 03 medical and health sciences, Prostate cancer, 0302 clinical medicine, Self help groups, Prostate, Inhibiteur PDE5, medicine, Prostate Neoplasm, Erectile dysfunction, Self report, Orgasm, Gynecology, business.industry, Orgasme, Cancer, medicine.disease, 3. Good health, medicine.anatomical_structure, 030220 oncology & carcinogenesis, PDE5-inhibitors, Prostate neoplasm, Cancer de prostate, business, Sexuality, After treatment
Abstract: Resume Introduction Les complications des traitements du cancer de la prostate sont responsables d’une alteration de la qualite de vie. Nous avons evalue la prevalence et le vecu par les patients des consequences fonctionnelles sexuelles des traitements du cancer de la prostate. Materiel et methodes un auto-questionnaire retrospectif a ete adresse a tous les membres de l’Association nationale des malades du cancer de la prostate (Anamacap). Toutes les reponses recues ont ete analysees. Resultats 226 questionnaires ont ete analyses, l’âge moyen etait de 67,3 ans, le suivi moyen de 58,1 mois. 110 patients ont eu une chirurgie seule, 29 une radio-hormonotherapie, 28 une irradiation seule et 49 des traitements combines. Apres le traitement du cancer de la prostate, une dysfonction erectile moderee a severe a ete rapportee par 75,2 % des patients ; une dysorgasmie etait retrouvee dans 69 % des cas ; une orgasmurie dans 21 % des cas ; une diminution de taille de la verge dans 70 % des cas et une diminution de sensibilite du gland dans 59 % des cas. Chacune entrainait une gene importante allant de 75 % a 90 % selon le symptome. La prise d’IPDE5 n’a montre une efficacite que dans 25,6 % en prise quotidienne et 39 % a la demande. Conclusion Les consequences fonctionnelles des traitements du cancer de la prostate sont frequentes, variees et imputent au premier plan la vie sexuelle. Il est necessaire d’ameliorer l’education therapeutique et la prise en charge oncosexologique grâce aux associations de malade, afin de retablir l’equilibre du couple. Niveau de preuve 3.
Published: 2017

42. Chemotherapy in hormone-sensitive metastatic prostate cancer: Evidences and uncertainties from the literature

Author: Marc-Olivier Timsit, Xavier Rebillard, Gwenaelle Gravis, Stéphane Oudard, Sébastien Vincendeau, Pierre Richaud, Jacques Irani, Aude Flechon, Claude Linassier, Morgan Rouprêt, Philippe Beuzeboc, Philippe Barthélémy, François Rozet, Laurence Albiges, Antoine Thiery Vuillemin, François Audenet, Service d'Oncologie Médicale [Marseille], Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC), Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Service d'urologie, Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Bicêtre, Service d'oncologie médicale [CHU Strasbourg], CHU Strasbourg, Department of Medical Oncology, Institut Curie [Paris], Service d'Oncologie Médicale [Centre hospitalier Lyon Sud - HCL], Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Service d'oncologie médicale, Centre Hospitalier Régional Universitaire de Tours (CHRU Tours)-Hôpital Bretonneau, Clinique Beau Soleil [Montpellier], Institut des Biomolécules Max Mousseron [Pôle Chimie Balard] (IBMM), Ecole Nationale Supérieure de Chimie de Montpellier (ENSCM)-Institut de Chimie du CNRS (INC)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), Institut Bergonié [Bordeaux], UNICANCER, Service d'Urologie [CHU Pitié-Salpêtrière], CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Service d'Oncologie Médicale [CHRU Besançon], Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Service d'urologie [Rennes] = Urology [Rennes], Hôpital Pontchaillou-CHU Pontchaillou [Rennes], Oncologie génito-urinaire, Département de médecine oncologique [Gustave Roussy], Institut Gustave Roussy (IGR)-Institut Gustave Roussy (IGR), Service d'Oncologie Médicale [Montsouris], Institut Mutualiste de Montsouris (IMM), Hôpital Bicêtre-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris-Sud - Paris 11 (UP11), Clinique Beausoleil, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), and Hôpital Bretonneau-Centre Hospitalier Régional Universitaire de Tours (CHRU Tours)
Subjects: Male, Oncology, medicine.medical_specialty, Combination therapy, Health Status, medicine.medical_treatment, [SDV.CAN]Life Sciences [q-bio]/Cancer, Docetaxel, [SDV.MHEP.UN]Life Sciences [q-bio]/Human health and pathology/Urology and Nephrology, law.invention, Androgen deprivation therapy, 03 medical and health sciences, Prostate cancer, 0302 clinical medicine, Randomized controlled trial, law, Prednisone, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, Humans, Medicine, Radiology, Nuclear Medicine and imaging, 030212 general & internal medicine, Neoplasm Metastasis, Chemotherapy, Evidence-Based Medicine, Performance status, business.industry, Patient Selection, Age Factors, Uncertainty, Prostatic Neoplasms, Androgen Antagonists, General Medicine, medicine.disease, Tumor Burden, 3. Good health, Population Surveillance, 030220 oncology & carcinogenesis, Disease Progression, Taxoids, Neoplasm Grading, business, medicine.drug
Abstract: International audience; Data from the literature support with strong evidence the addition of docetaxel to androgen-deprivation therapy (ADT) for men with metastatic prostate cancer, and starting therapy for the first time. A meta-analysis of three randomized controlled trials showed a significant improvement of overall survival when ADT was combined with docetaxel when compared to ADT alone (HR = 0.77; 95% CI: 0.68–0.87; p < 0.0001). Consequently, combination therapy should be considered presently as the new standard of care, using 6 cycles of docetaxel, without prednisone.However, candidates for this upfront combination therapy in whom the balance between its side effects and benefits is favorable are still to be identified more precisely. Patients’ stratification according to Gleason score, previous local treatment and age or performance status were shown to have a prognostic impact. The volume of metastases, as defined in the CHAARTED study for instance, could be an interesting predictive factor. However, data accumulated until now remain only hypothesis generating and further analysis and studies are needed to establish any potential discriminating factors.Several new efficient therapeutic options are now available in prostate cancer management and should be evaluated against a chemo-hormonal combination therapy. Other trials are warranted to establish the role of docetaxel in earlier stages of the disease, the combination with the new hormonal therapies as well as the best management options after docetaxel.
Published: 2017

43. Added value of hepcidin quantification for the diagnosis and follow-up of anemia-related diseases

Author: Thibaud Lefebvre, Martine Fénéant-Thibault, Constance Delaby, Patricia Aguilar-Martinez, Sigismond Lasocki, Sylvain Lehmann, Pierre-Jean Lamy, Madeleine Ropert-Bouchet, Séverine Cunat, Centre de recherche sur l'Inflammation (CRI (UMR_S_1149 / ERL_8252 / U1149)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Diderot - Paris 7 (UPD7), Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM), AP-HP Hôpital Bicêtre (Le Kremlin-Bicêtre), Clinique Beau Soleil [Montpellier], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), CHU Pontchaillou [Rennes], Département d'hématologie biologique[Montpellier], Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-CHU Saint-Eloi, Cellules Souches, Plasticité Cellulaire, Médecine Régénératrice et Immunothérapies (IRMB), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), and Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)
Subjects: Hemolytic anemia, Anemia, Iron, Inflammation, 03 medical and health sciences, 0302 clinical medicine, Hepcidins, Hepcidin, Predictive Value of Tests, hemic and lymphatic diseases, medicine, Homeostasis, Humans, Monitoring, Physiologic, biology, business.industry, Iron levels, nutritional and metabolic diseases, General Medicine, Hypoxia (medical), medicine.disease, Prognosis, 3. Good health, 030220 oncology & carcinogenesis, Immunology, biology.protein, Erythropoiesis, hepcidin, medicine.symptom, business, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology, Biomarkers, 030215 immunology
Abstract: International audience; Iron homeostasis is based on a strict control of both intestinal iron absorption and iron recycling through reticulo-endothelial system. Hepcidin controls the iron fluxes in order to maintain sufficient iron levels for erythropoietic activities, hemoproteins synthesis or enzymes function, but also to limit its toxic accumulation throughout the body. Hepcidin expression is regulated by various stimuli: inflammation and iron stimulate the production of the peptide, while anemia, erythropoiesis and hypoxia repress its production. Regulation of hepcidin expression is not so simple in complex pathological situations such as hemolytic anemia, cancer or chronic inflammation. Serum hepcidin quantification in association with the diagnostic tests currently available is quite promising for the diagnosis or the follow-up of anemia in those conditions. This study is part of the working group « Clinical interests of hepcidin quantification » of the Société française de biologie clinique.
Published: 2017

44. Radium 223 dichloride for prostate cancer treatment

Author: Mathieu Roumiguié, Philippe Beuzeboc, Constance Thibault, François Rozet, Diana Kassab-Chahmi, Florent Cachin, Damien Huglo, Nadine Houédé, Emmanuel Deshayes, Christophe Hennequin, Xavier Rebillard, Urologie, andrologie et transplantation rénale, CHU Toulouse [Toulouse]-Hôpital de Rangueil, CHU Toulouse [Toulouse], Department of Medical Oncology, Institut Curie [Paris], Centre Jean Perrin [Clermont-Ferrand] (UNICANCER/CJP), UNICANCER, Imagerie Moléculaire et Stratégies Théranostiques (IMoST), Université Clermont Auvergne [2017-2020] (UCA [2017-2020])-Institut National de la Santé et de la Recherche Médicale (INSERM), Sorbonne Université (SU), Therapies Interventionnelles Assistees Par l'Image et la Simulation, Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille, Droit et Santé, Service d'Oncologie Médicale [Montsouris], Institut Mutualiste de Montsouris (IMM), Service d'urologie, Clinique Beausoleil, Institut Bergonié [Bordeaux], Institut de Recherche en Cancérologie de Montpellier (IRCM - U1194 Inserm - UM), CRLCC Val d'Aurelle - Paul Lamarque-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Institut du Cancer de Montpellier (ICM), Département d'Urologie-Andrologie et Transplantation Rénale [CHU Toulouse], Pôle Urologie - Néphrologie - Dialyse - Transplantations - Brûlés - Chirurgie plastique - Explorations fonctionnelles et physiologiques [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Clermont Auvergne [2017-2020] (UCA [2017-2020]), Hopital Saint-Louis [AP-HP] (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Therapies Interventionnelles Assistees Par l'Image et la Simulation - U 703 (Thiais), Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Clinique Beau Soleil [Montpellier], Institut des Biomolécules Max Mousseron [Pôle Chimie Balard] (IBMM), Ecole Nationale Supérieure de Chimie de Montpellier (ENSCM)-Institut de Chimie du CNRS (INC)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), and CACHIN, Florent
Subjects: Male, 0301 basic medicine, Oncology, Drug, medicine.medical_specialty, media_common.quotation_subject, [SDV]Life Sciences [q-bio], Pharmaceutical Science, mechanism, Antineoplastic Agents, Bone Neoplasms, Review, Malignant disease, 03 medical and health sciences, Prostate cancer, 0302 clinical medicine, Prostate, Internal medicine, Drug Discovery, Tumor Microenvironment, medicine, Tumor cell death, Animals, Humans, DNA Breaks, Double-Stranded, Radium-223 Dichloride, development, media_common, bone metastasis, Radioisotopes, Pharmacology, Drug Design, Development and Therapy, business.industry, Bone metastasis, drug, mCRPC, medicine.disease, 3. Good health, agents, Clinical trial, [SDV] Life Sciences [q-bio], Prostatic Neoplasms, Castration-Resistant, 030104 developmental biology, medicine.anatomical_structure, 030220 oncology & carcinogenesis, business, Radium
Abstract: Emmanuel Deshayes,1,2 Mathieu Roumiguie,3 Constance Thibault,4 Philippe Beuzeboc,5 Florent Cachin,6 Christophe Hennequin,7 Damien Huglo,8 François Rozet,9 Diana Kassab-Chahmi,10 Xavier Rebillard,11 Nadine Houédé1,12 1Radiobiology Unit, INSERM U1194, Institut du Cancer de Montpellier (ICM), 2Department of Nuclear Medicine, Institut du Cancer de Montpellier (ICM), Montpellier, 3Urology Department, Andrology and Renal Transplantation, CHU Rangueil, Toulouse, 4Medical Oncology Department, Hôpital Européen Georges Pompidou, 5Oncology Department, Institut Curie, 6Department of Nuclear Medicine, CHU, Clermont-Ferrand, 7Radiotherapy Department, Hôpital Saint Louis, Paris, 8Department of Nuclear Medicine, CHRU, Lille, 9Urology Department, Institut Mutualiste Montsouris, 10Intergroupe coopérateur francophone de recherche en onco-urologie, Paris, 11Urology Department, Clinique BeauSoleil, Montpellier, 12Medical Oncology Department, Institut de Cancérologie du Gard – CHU Caremeau, Nîmes, France Abstract: Prostate cancer is the most common malignant disease in men. Several therapeutic agents have been approved during the last 10 years. Among them, radium-223 dichloride (Xofigo®) is a radioactive isotope that induces irreversible DNA double-strand breaks and consequently tumor cell death. Radium-223 dichloride is acalcium-mimetic agent that specifically targets bone lesions. Radium-223 dichloride has been approved for the treatment of metastatic castration-resistant prostate cancer with symptomatic bone metastases, without known visceral metastases. In this review, first we summarize the interplay between prostate tumor cells and bone microenvironment; then, we discuss radium-223 dichloride mechanism of action and present the results of the available clinical trials and future developments for this new drug. Keywords: bone metastasis, mCRPC, mechanism, drug, agents, development&nbsp
Published: 2017

45. Technique of Injection of Hyaluronic Acid as a Prostatic Spacer and Fiducials Before Hypofractionated External Beam Radiotherapy for Prostate Cancer

Author: A. Faix, O. Chapet, Xavier Rebillard, Corina Udrescu, Philippe Paparel, Romain Boissier, Alain Ruffion, Jean-Etienne Terrier, Marian Devonec, David Azria, Chirurgie urologique et transplantation rénale [Hôpital de la Conception - APHM], Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM)-Hôpital de la Conception [CHU - APHM] (LA CONCEPTION), Vascular research center of Marseille (VRCM), Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut des Biomolécules Max Mousseron [Pôle Chimie Balard] (IBMM), Centre National de la Recherche Scientifique (CNRS)-Institut de Chimie du CNRS (INC)-Université de Montpellier (UM)-Ecole Nationale Supérieure de Chimie de Montpellier (ENSCM), Service d'urologie, Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Ciblage thérapeutique en Oncologie (EA3738), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon, Institut de Recherche en Cancérologie de Montpellier (IRCM - U1194 Inserm - UM), CRLCC Val d'Aurelle - Paul Lamarque-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Hospices Civils de Lyon (HCL), Service d'urologie [Centre Hospitalier Lyon Sud - HCL], Ecole Nationale Supérieure de Chimie de Montpellier (ENSCM)-Institut de Chimie du CNRS (INC)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), and Clinique Beau Soleil [Montpellier]
Subjects: Male, medicine.medical_specialty, Urology, medicine.medical_treatment, [SDV]Life Sciences [q-bio], Rectum, Endosonography, Injections, 030218 nuclear medicine & medical imaging, 03 medical and health sciences, Prostate cancer, 0302 clinical medicine, Fiducial Markers, Prostate, medicine, Humans, Local anesthesia, External beam radiotherapy, Hyaluronic Acid, Radiation Injuries, ComputingMilieux_MISCELLANEOUS, Aged, Viscosupplements, medicine.diagnostic_test, business.industry, Dose fractionation, Prostatic Neoplasms, Magnetic resonance imaging, Middle Aged, medicine.disease, Magnetic Resonance Imaging, 3. Good health, Surgery, Radiation therapy, Treatment Outcome, medicine.anatomical_structure, 030220 oncology & carcinogenesis, Dose Fractionation, Radiation, Radiotherapy, Intensity-Modulated, Nuclear medicine, business, Radiotherapy, Image-Guided
Abstract: Objective To describe a technique combining the implantation of fiducials and a prostatic spacer (hyaluronic acid [HA]) to decrease the rectal toxicity after an image-guided external beam radiotherapy (EBRT) with hypofractionation for prostate cancer and to assess the tolerance and the learning curve of the procedure. Materials and Methods Thirty patients with prostate cancer at low or intermediate risk were included in a phase II trial: image-guided EBRT of 62 Gy in 20 fractions of 3.1 Gy with intensity-modulated radiotherapy. A transrectal implantation of 3 fiducials and transperineal injection of 10 cc of HA (NASHA gel spacer, Q-Med AB, Uppsala, Sweden) between the rectum and the prostate was performed by 1 operator. The thickness of HA was measured at 10 points on magnetic resonance imaging to establish a quality score of the injection (maximum score = 10) and determine the learning curve of the procedure. Results The quality score increased from patients 1-10, 11-20, to 21-30 with respective median scores: 7 [2-10], 5 [4-7], and 8 [3-10]. The average thicknesses of HA between the base, middle part, and apex of the prostate and the rectum were the following: 15.1 mm [6.4-29], 9.8 mm [5-21.2], and 9.9 mm [3.2-21.5]. The injection of the HA induced a median pain score of 4 [1-8] and no residual pain at mid-long term. Conclusion Creating an interface between the rectum and the prostate and the implantation of fiducials were feasible under local anesthesia with a short learning curve and could become a standard procedure before a hypofractionated EBRT for prostate cancer.
Published: 2017

46. Prostate Hypofractionated Radiation Therapy (62 Gy at 3.1 Gy Per Fraction) With Injection of Hyaluronic Acid: Final Results of the RPAH1 Study

Author: Alain Ruffion, O. Chapet, Sylvie Bin, Ciprian Enachescu, D. Azria, P. Fenoglietto, A. Faix, S. Yossi, Corina Udrescu, P. Jalade, Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL), Pôle Information Médicale Evaluation Recherche (IMER), CRLCC Val d'Aurelle - Paul Lamarque, Clinique Beau Soleil [Montpellier], Institut de Recherche en Cancérologie de Montpellier (IRCM - U1194 Inserm - UM), and CRLCC Val d'Aurelle - Paul Lamarque-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)
Subjects: Cancer Research, Radiation, Hypofractionated Radiation Therapy, business.industry, Fraction (chemistry), [SDV.CAN]Life Sciences [q-bio]/Cancer, 030218 nuclear medicine & medical imaging, 3. Good health, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, medicine.anatomical_structure, Oncology, chemistry, Prostate, 030220 oncology & carcinogenesis, Hyaluronic acid, medicine, Radiology, Nuclear Medicine and imaging, Nuclear medicine, business, ComputingMilieux_MISCELLANEOUS, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract: International audience
Published: 2016

47. Metastatic Prostate Cancer Incidence and Prostate-specific Antigen Testing: New Insights from the European Randomized Study of Screening for Prostate Cancer

Author: Louis Denis, Jonas Hugosson, Arnauld Villers, Teuvo L.J. Tammela, Marco Zappa, Chris H. Bangma, Harry J. de Koning, Alvaro Paez, Maciej Kwiatkowski, Carlotta Buzzoni, Sigrid Carlsson, Vera Nelen, Marcos Lujan, Xavier Rebillard, Marco Randazzo, Fritz H. Schröder, Monique J. Roobol, Anssi Auvinen, Sue Moss, Donella Puliti, University of Tampere [Finland], Erasmus University Medical Center [Rotterdam] (Erasmus MC), Sahlgrenska Academy at University of Gothenburg [Göteborg], Memorial Sloane Kettering Cancer Center [New York], Queen Mary University of London (QMUL), University hospital of Zurich [Zurich], Clinique Beau Soleil [Montpellier], Institut des Biomolécules Max Mousseron [Pôle Chimie Balard] (IBMM), Ecole Nationale Supérieure de Chimie de Montpellier (ENSCM)-Institut de Chimie du CNRS (INC)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), Tampere University Hospital, Université de Lille, Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Urology, and Public Health
Subjects: Male, Oncology, 030232 urology & nephrology, urologic and male genital diseases, [SDV.MHEP.UN]Life Sciences [q-bio]/Human health and pathology/Urology and Nephrology, law.invention, Metastasis, Prostate cancer, PSA, 0302 clinical medicine, Randomized controlled trial, law, Neoplasm Metastasis, Stage (cooking), Early Detection of Cancer, Incidence, Incidence (epidemiology), Middle Aged, Mortality reduction, 3. Good health, Prostate-specific antigen, 030220 oncology & carcinogenesis, symbols, Regression Analysis, Kallikreins, Risk assessment, medicine.medical_specialty, Prostate screening, Urology, [SDV.CAN]Life Sciences [q-bio]/Cancer, Risk Assessment, Article, 03 medical and health sciences, symbols.namesake, SDG 3 - Good Health and Well-being, Internal medicine, medicine, Humans, Poisson regression, Aged, Neoplasm Staging, Gynecology, business.industry, Prostatic Neoplasms, Prostate-Specific Antigen, medicine.disease, Metastatic cancer incidence, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, Neoplasm Grading, business
Abstract: Background: The European Randomized Study of Screening for Prostate Cancer (ERSPC) has shown a 21% reduction in prostate cancer (PCa) mortality and a 1.6-fold increase in PCa incidence with prostate-specific antigen (PSA)-based screening (at 13 yr of follow-up). We evaluated PCa incidence by risk category at diagnosis across the study arms to assess the potential impact on PCa mortality. Design, setting, and participants: Information on arm, centre, T and M stage, Gleason score, serum PSA at diagnosis, age at randomisation, follow-up time, and vital status were extracted from the ERSPC database. Four risk categories at diagnosis were defined: 1, low; 2, intermediate; 3, high; 4, metastatic disease. PSA ( 100 ng/ml) was used as the indicator of metastasis. Outcome measurements and statistical analysis: Incidence rate ratios (IRRs) for screening versus control arm by risk category at diagnosis and follow-up time were calculated using Poisson regression analysis for seven centres. Follow-up was truncated at 13 yr. Missing data were imputed using chained equations. The analyses were carried out on an intention-to-treat basis. Results and limitations: In the screening arm, 7408 PCa cases were diagnosed and 6107 in the control arm. The proportion of missing stage, Gleason score, or PSA value was comparable in the two arms (8% vs 10%), but differed among centres. The IRRs were elevated in the screening arm for the low-risk (IRR: 2.14; 95% CI, 2.03-2.25) and intermediate-risk (IRR: 1.24; 95% CI, 1.16-1.34) categories at diagnosis, equal to unity for the high-risk category at diagnosis (IRR: 1.00; 95% CI, 0.89-1.13), and reduced for metastatic disease at diagnosis (IRR: 0.60; 95% CI, 0.52-0.70). The IRR of metastatic disease had temporal pattern similar to mortality, shifted forwards an average of almost 3 yr, although the mortality reduction was smaller. Conclusions: The results confirm a reduction in metastatic disease at diagnosis in the screening arm, preceding mortality reduction by almost 3 yr. Patient summary: The findings of this study indicate that the decrease in metastatic disease at diagnosis is the major determinant of the prostate cancer mortality reduction in the European Randomized study of Screening for Prostate Cancer. (C) 2015 European Association of Urology. Published by Elsevier B.V. All rights reserved.
Published: 2016

48. High EGFR protein expression and exon 9 PIK3CA mutations are independent prognostic factors in triple negative breast cancers

Author: Caroline Mollevi, Evelyne Lopez-Crapez, Pierre-Emmanuel Colombo, Pierre-Jean Lamy, Frédéric Bibeau, Pierre-Marie Martin, William Jacot, Gilles Romieu, Frédéric Fina, CRLC Val d'Aurelle-Paul Lamarque, CRLCC Val d'Aurelle - Paul Lamarque, Institut de Recherche en Cancérologie de Montpellier (IRCM - U1194 Inserm - UM), CRLCC Val d'Aurelle - Paul Lamarque-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), UNICANCER - Institut régional du Cancer Montpellier Val d'Aurelle (ICM), Aix-Marseille Université - Faculté de médecine (AMU MED), Aix Marseille Université (AMU), Département d'oncologie Médicale, Lab-STICC_UBO_MOM_DIM, Laboratoire des sciences et techniques de l'information, de la communication et de la connaissance (Lab-STICC), École Nationale d'Ingénieurs de Brest (ENIB)-Université de Bretagne Sud (UBS)-Université de Brest (UBO)-Télécom Bretagne-Institut Brestois du Numérique et des Mathématiques (IBNM), Université de Brest (UBO)-Université européenne de Bretagne - European University of Brittany (UEB)-École Nationale Supérieure de Techniques Avancées Bretagne (ENSTA Bretagne)-Institut Mines-Télécom [Paris] (IMT)-Centre National de la Recherche Scientifique (CNRS)-École Nationale d'Ingénieurs de Brest (ENIB)-Université de Bretagne Sud (UBS)-Université de Brest (UBO)-Télécom Bretagne-Institut Brestois du Numérique et des Mathématiques (IBNM), Université de Brest (UBO)-Université européenne de Bretagne - European University of Brittany (UEB)-École Nationale Supérieure de Techniques Avancées Bretagne (ENSTA Bretagne)-Institut Mines-Télécom [Paris] (IMT)-Centre National de la Recherche Scientifique (CNRS), Assistance Publique - Hôpitaux de Marseille (APHM), Laboratoire d'anatomo-pathologie, Clinique Beau Soleil [Montpellier], KARLI, Mélanie, Université européenne de Bretagne - European University of Brittany (UEB)-École Nationale d'Ingénieurs de Brest (ENIB)-Université de Bretagne Sud (UBS)-Université de Brest (UBO)-Télécom Bretagne-Institut Brestois du Numérique et des Mathématiques (IBNM), Université de Brest (UBO)-École Nationale Supérieure de Techniques Avancées Bretagne (ENSTA Bretagne)-Institut Mines-Télécom [Paris] (IMT)-Centre National de la Recherche Scientifique (CNRS)-Université européenne de Bretagne - European University of Brittany (UEB)-École Nationale d'Ingénieurs de Brest (ENIB)-Université de Bretagne Sud (UBS)-Université de Brest (UBO)-Télécom Bretagne-Institut Brestois du Numérique et des Mathématiques (IBNM), and Université de Brest (UBO)-École Nationale Supérieure de Techniques Avancées Bretagne (ENSTA Bretagne)-Institut Mines-Télécom [Paris] (IMT)-Centre National de la Recherche Scientifique (CNRS)
Subjects: Oncology, CA15-3, PTEN, Cancer Research, Triple Negative Breast Neoplasms, PI3K, Phosphatidylinositol 3-Kinases, Exon, Breast cancer, Surgical oncology, Medicine, Aged, 80 and over, education.field_of_study, [SDV.MHEP] Life Sciences [q-bio]/Human health and pathology, biology, Exons, Middle Aged, Prognosis, 3. Good health, ErbB Receptors, Gene Expression Regulation, Neoplastic, Female, Research Article, Adult, medicine.medical_specialty, Class I Phosphatidylinositol 3-Kinases, EGFR, Population, [SDV.CAN]Life Sciences [q-bio]/Cancer, [SDV.CAN] Life Sciences [q-bio]/Cancer, Internal medicine, Genetics, Humans, EGFR Gene Amplification, education, Aged, Gene amplification, business.industry, PTEN Phosphohydrolase, medicine.disease, Mutation, Cancer research, biology.protein, Triple negative, business, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract: Background Triple negative breast cancers (TNBC) are a more aggressive subset of breast cancer. A better understanding of its biology could allow the rational development of targeted therapies. Methods We extensively analyzed the EGFR/PI3K/PTEN axis in a large, homogeneous population of TNBC to help defining the putative role of anti-EGFR and -PI3K targeted therapies in this setting. EGFR gene amplification, EGFR protein expression, PIK3CA and PTEN gene alterations (two members of EGFR downstream pathways) and their clinicopathological and prognostic implications were analyzed in 204 TNBC samples from European patients. Results EGFR amplification was detected in 18 of the 204 TNBC specimens (8.9 %) and was significantly associated with higher EGFR protein levels. Fourteen PIK3CA mutations were identified in exon 9 (6.7 %), and 17 in exon 20 (8.3 %). PIK3CA mutations, especially in exon 9, were significantly associated with grade I-II tumors. PTEN deletions were detected in 43 samples (21.50 %) and were significantly associated with grade III tumors (p
Published: 2015

49. Abiraterone acetate in patients with metastatic castration-resistant prostate cancer: long term outcome of the Temporary Authorization for Use programme in France

Author: Remy Delva, Philippe Beuzeboc, Stéphane Oudard, Nadine Houédé, Brigitte Laguerre, Delphine Topart, Sophie Gourgou, Igor Latorzeff, Hanane Agherbi, Gwenaelle Gravis, Xavier Rebillard, Guilhem Roubaud, Sophie Tartas, Aude Fléchon, Laura Moise, Diego Tosi, Jean-Marc Ferrero, David Azria, Service d'Oncologie Médicale [Nîmes], Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), Institut de Recherche en Cancérologie de Montpellier (IRCM - U1194 Inserm - UM), CRLCC Val d'Aurelle - Paul Lamarque-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Service d'Oncologie Médicale [Paris], Institut Curie [Paris], Service d'Oncologie Médicale [Caen], Centre Régional de Lutte contre le Cancer François Baclesse [Caen] (UNICANCER/CRLC), UNICANCER-Tumorothèque de Caen Basse-Normandie (TCBN)-Normandie Université (NU)-UNICANCER-Tumorothèque de Caen Basse-Normandie (TCBN)-Normandie Université (NU), Service d'Oncologie Médicale [Marseille], Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC), Service d'Oncologie Médicale [Angers], Centre Paul Papin, Service d'Oncologie Médicale [Lyon], UNICANCER - Centre Léon Bérard Lyon (Rhône), Clinique Pasteur, Toulouse, Service d'Oncologie Médicale [Nice], Centre de Lutte contre le Cancer Antoine Lacassagne [Nice] (UNICANCER/CAL), UNICANCER-Université Côte d'Azur (UCA)-UNICANCER-Université Côte d'Azur (UCA), Service d'oncologie médicale [CHU HEGP], Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Service d'Oncologie Médicale [Centre hospitalier Lyon Sud - HCL], Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Service d'Oncologie Médicale [Rennes], CRLCC Eugène Marquis (CRLCC), Service d'oncologie médicale [CHU Montpellier], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Service d'Oncologie Médicale [Bordeaux], Institut Bergonié [Bordeaux], UNICANCER-UNICANCER, Service d'urologie, Clinique Beausoleil, BMC, BMC, Service d'Oncologie médicale [CHU Caen], CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Clinique Beau Soleil [Montpellier], Institut des Biomolécules Max Mousseron [Pôle Chimie Balard] (IBMM), Ecole Nationale Supérieure de Chimie de Montpellier (ENSCM)-Institut de Chimie du CNRS (INC)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Régional Universitaire de Nîmes ( CHRU Nîmes ), Institut de Recherche en Cancérologie de Montpellier ( IRCM - U1194 Inserm - UM ), CRLCC Val d'Aurelle - Paul Lamarque-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Université de Montpellier ( UM ), INSTITUT CURIE, Centre Régional de Lutte contre le Cancer François Baclesse ( CRLC François Baclesse ), UNICANCER - Centre Antoine Lacassagne [Nice], Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Européen Georges Pompidou [APHP] ( HEGP ), Centre Hospitalier Lyon Sud [CHU - HCL] ( CHLS ), Hospices Civils de Lyon ( HCL ) -Hospices Civils de Lyon ( HCL ), CRLCC Eugène Marquis ( CRLCC ), Centre Hospitalier Régional Universitaire [Montpellier] ( CHRU Montpellier ), and UNICANCER - Institut Bergonié [Bordeaux]
Subjects: Oncology, Male, Cancer Research, Multivariate analysis, medicine.medical_treatment, [SDV]Life Sciences [q-bio], Metastasis, Cohort Studies, chemistry.chemical_compound, Prostate cancer, 0302 clinical medicine, Surgical oncology, Antineoplastic Combined Chemotherapy Protocols, Neoplasm Metastasis, Aged, 80 and over, 0303 health sciences, Prognostic factor, Abiraterone acetate, Middle Aged, Prognosis, 3. Good health, [SDV] Life Sciences [q-bio], Prostatic Neoplasms, Castration-Resistant, Treatment Outcome, Docetaxel, 030220 oncology & carcinogenesis, France, medicine.drug, Cohort study, Research Article, medicine.medical_specialty, Efficacy, Antineoplastic Agents, 03 medical and health sciences, Internal medicine, medicine, Genetics, Humans, 030304 developmental biology, Aged, Gynecology, Chemotherapy, [ SDV ] Life Sciences [q-bio], business.industry, medicine.disease, Metastatic castration-resistant prostate cancer, chemistry, Neoplasm Grading, business, Follow-Up Studies
Abstract: International audience; AbstractBackgroundCOU-AA-301 trial has proved that abiraterone acetate (AA), a selective inhibitor of androgen biosynthesis, improved overall survival (OS) of patients with metastatic castration resistant prostate cancer (mCRPC) after a first line of docetaxel. Based on this result, a Temporary Authorization for Use (TAU) was performed between December 2010 and July 2011 to provide patients with mCRPC the opportunity to receive AA before its commercialization. The aim of this study was to evaluate safety and efficacy of AA treatment in this TAU.MethodsBetween December 2010 and July 2011, we conducted an ambispective, multicentric cohort study and investigated data from 20 centres participating to the AA TAU for patients presenting mCRPC and already treated by a first line of chemotherapy (CT). Statistical analyses of the data were performed using the Stata software v13 to identify predictive and prognostic factors.ResultsAmong the 408 patients, 306 were eligible with a follow-up at 3 years. Median OS was 37.1 months from beginning of CT and 14.6 months from AA introduction. 211 patients (69%) received ≥ 3 months of AA and 95 patients (31%) were treated less than 3 months. In the multivariate analyses, duration of AA was significantly correlated with PSA decrease at 3 months. Additionally, shorter time under AA treatment, presence of multiple sites of metastasis and previous hormonal treatment duration were three independent factors associated with poorer OS. At the time of analysis ten patients were still under treatment for more than 3 years.ConclusionsBiochemical response monitored by PSA changes at 3 months is a strong predictive factor for AA treatment duration. Some high responders’ patients could beneficiate from AA for more than 3 years.
Published: 2015

50. Impact of prostate cancer diagnosis and type of treatment on the health-related quality of life and urological dysfunction at 3 years: A case-control study

Author: Nadine Houede, Sophie Bouvet, Xavier Rebillard, Frédéric Fiteni, Brigitte Trétarre, Florence Menegaux, Christel Castelli, Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, Clinique Beau Soleil [Montpellier], Institut des Biomolécules Max Mousseron [Pôle Chimie Balard] (IBMM), Ecole Nationale Supérieure de Chimie de Montpellier (ENSCM)-Institut de Chimie du CNRS (INC)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), Registre des Tumeurs de l'Hérault, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Institut du Cancer de Montpellier (ICM), Laboratoire de Biostatistique, Epidémiologie clinique, Santé Publique Innovation et Méthodologie [CHU Nîmes] (BESPIM), Hôpital Universitaire Carémeau [Nîmes] (CHU Nîmes), Centre Hospitalier Universitaire de Nîmes (CHU Nîmes)-Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), Institut de Recherche en Cancérologie de Montpellier (IRCM - U1194 Inserm - UM), and CRLCC Val d'Aurelle - Paul Lamarque-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)
Subjects: Health related quality of life, Cancer Research, medicine.medical_specialty, business.industry, Urinary system, medicine.medical_treatment, Case-control study, [SDV.CAN]Life Sciences [q-bio]/Cancer, medicine.disease, Radiation therapy, Prostate cancer, Oncology, Internal medicine, medicine, business
Abstract: International audience; Background: Former studies showed a time-dependent worsening of sexual or urinary long term side effects following surgery or radiotherapy that affected prostate cancer (PCa) patients’ health-related quality of life (HRQoL) though it was not possible to discriminate between age- and treatment-related symptoms. We sought to compare HRQoL and urological dysfunction at 3 years between PCa patients and general population based on the data from the EPICAP population-based case-control study. Methods: Eligible cases were men < 75 years old, diagnosed with PCa between 2012 and 2014. Controls were recruited in the general population and paired on age. Questionnaires were given to the patients at 3 years after intervention. Primary objective was to compare HRQoL using the EORTC QLQ-C30 questionnaire at 3 years between patients and the general population. Secondary objective was to perform the same comparison for the impact of diagnosis or/and treatments on urinary (IPSS, ICS) or sexual dysfunctions (IEEF-5), anxiety (HADS), and occupational integration. Results: 376 eligible patients had sent back their questionnaires and 188 controls were paired on age (ratio 2:1). Treatments were: RP (radical prostatectomy) (187), RT (radiation therapy) or HIFU (High-intensity Focused Ultrasound) (54), combination of treatment (CT) (90) and watchful waiting (WW) (39) at the time of the study. There was no difference in global health status dimension between patients and controls (p = 0.19). Patients had worse social functioning than controls (24.3% vs 16.3%, p = 0.0209) and cognitive function score was worse in CT versus WW patients (p = 0.039). Significant differences in erectile dysfunction (IIEF6) were observed depending on treatment (81% for RP vs 65% for RT vs 72% for CT vs 33% for WW, p < 0.0001). Conclusions: Despite similar global health status dimension score at 3 years after diagnosis between patients and controls, analyzes of the EPICAP study showed differences in PCa sequelae and emphasize the balance between benefit and risk of PSA testing. This is the first study evaluating the different types of sequelae as a function of treatments.
Published: 2018

Catalog

Books, media, physical & digital resources

See catalog results

Searchworks

Select search scope, currently: Articles Catalog books, media & more in Jio Institute collections Articles journal articles & other e-resources

Search

Search Constraints

Refine your results

Search Limiters

Topic

Publication Year Range

Language

Journal

Database

Publisher

56 results on '"Clinique Beau Soleil [Montpellier]"'

Search Results

Catalog

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources